Xeriant (XERI) S-1/A 2 May 23 IPO registration (amended) Financial data

Cover

Cover	6 Months Ended
	Dec. 31, 2022
Cover [Abstract]
Entity Registrant Name	XERIANT, INC.
Entity Central Index Key	0001481504
Document Type	S-1/A
Amendment Flag	true
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Filer Category	Non-accelerated Filer
Entity Incorporation State Country Code	NV
Entity Tax Identification Number	27-1519178
Entity Address Address Line 1	Innovation Centre 1 3998 FAU Boulevard
Entity Address Address Line 2	Suite 309
Entity Address City Or Town	Boca Raton
Entity Address State Or Province	FL
Entity Address Postal Zip Code	33431
City Area Code	561
Amendment Description	The registrant hereby amends this registration statement on such date or dates as may be necessary to delay its effective date until the registrant shall file a further amendment which specifically states that this registration statement shall thereafter become effective in accordance with Section 8(a) of the Securities Act of 1933 or until the registration statement shall become effective on such date as the Securities and Exchange Commission, acting pursuant to said Section 8(a), may determine.
Local Phone Number	491-9595

CONDENSED CONSOLIDATED BALANCE

CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)	Dec. 31, 2022	Jun. 30, 2022	Jun. 30, 2021
Current assets
Cash	$ 119,593	$ 1,065,945	$ 962,540
Deposits	12,546	12,546	13,780
Investment in JV with Ebenberg LLC	107,928	57,678	0
Prepaids	10,515	756
Total current assets	250,582	1,136,925	976,320
Property & equipment, net	6,263	4,409
Operating lease right-of-use asset	106,239	128,342	169,209
Total assets	363,084	1,269,676	1,145,529
Current liabilities
Accounts payable and accrued liabilities	157,869	56,836	73,224
Accrued liabilities, related party	64,000	22,000	25,000
Shares to be issued	75,200	75,200	0
Convertible notes payable, net of discount	5,850,000	3,936,185	158,196
Lease liability, current	50,647	48,963	42,643
Total current liabilities	6,197,716	4,139,184	299,063
Lease liability, long-term	66,938	92,197	141,160
Total liabilities	6,264,654	4,231,381	440,223
Stockholders' deficit
Common stock, $0.00001 par value; 5,000,000,000 shares authorized; 376,933,144 and 365,239,001 shares issued and outstanding at December 31, 2022 and June 30, 2022, respectively	3,769	3,652	2,928
Common stock to be issued	51,950	51,950	51,090
Additional paid in capital	19,523,605	16,351,791	4,138,191
Accumulated deficit	(22,668,569)	(16,571,505)	(3,270,235)
Controlling interest	(3,089,227)	(164,094)	921,992
Non-controlling interest	(2,812,343)	(2,797,611)	(216,686)
Total stockholders' deficit	(5,901,570)	(2,961,705)	705,306
Total liabilities and stockholders' deficit	363,084	1,269,676	1,145,529
Series A, Preferred Stock
Stockholders' deficit
Preferred stock, value	8	8	8
Series B Preferred Shares [Member]
Stockholders' deficit
Preferred stock, value	$ 10	10
Series B Preferred Stock [Member]
Stockholders' deficit
Preferred stock, value		$ 10	$ 10

CONDENSED CONSOLIDATED BALANC_2

CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares	Dec. 31, 2022	Jun. 30, 2022	Jun. 30, 2021
Stockholders' deficit
Common stock, shares authorized	5,000,000,000	5,000,000,000	5,000,000,000
Common stock, shares par value	$ 0.00001	$ 0.00001	$ 0.00001
Common stock, shares issued	376,933,144	365,239,001	292,815,960
Common stock, shares outstanding	376,933,144	365,239,001	292,815,960
Series B Preferred Shares [Member]
Stockholders' deficit
Preferred stock, shares par value	$ 0.00001	$ 0.00001	$ 0.00001
Preferred stock, shares authorized	100,000,000	100,000,000	100,000,000
Preferred stock, shares designated	1,000,000	1,000,000	1,000,000
Preferred stock, shares issued	1,000,000	1,000,000	1,000,000
Preferred stock, shares outstanding	1,000,000	1,000,000	1,000,000
Series A Preferred Shares [Member]
Stockholders' deficit
Preferred stock, shares par value	$ 0.00001	$ 0.00001	$ 0.00001
Preferred stock, shares authorized	100,000,000	100,000,000	100,000,000
Preferred stock, shares designated	3,500,000	3,500,000	3,500,000
Preferred stock, shares issued	769,895	781,132	788,270
Preferred stock, shares outstanding	769,895	781,132	788,270

CONDENSED CONSOLIDATED STATEMEN

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED) - USD ($)	3 Months Ended		6 Months Ended		12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2022	Dec. 31, 2021	Jun. 30, 2022	Jun. 30, 2021
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED)
General and administrative expenses	$ 340,508	$ 1,120,250	$ 886,077	$ 2,321,252	$ 4,216,613	$ 368,296
Operating expenses:
Advertising and marketing expense					651,567	1,047,120
Professional fees	78,568	102,484	168,628	132,025	444,012	190,693
Related party consulting fees	118,000	130,925	212,000	213,425	432,425	220,000
Research and development expense	0	2,859,644	0	5,200,219	5,267,581	373,112
Total operating expenses	539,019	4,259,926	1,275,004	8,512,139	11,012,198	2,199,221
Sales and marketing expense	1,943	46,623	8,299	645,218
Loss from operations	(539,019)	(4,259,926)	(1,275,004)	(8,512,139)	(11,012,198)	(2,199,221)
Other expenses:
Amortization of debt discount	0	1,264,931	461,842	1,413,959	(4,629,089)	(303,942)
Financing fees	0	0	0	(43,750)	(43,750)
Interest expense	0	(1,625)	0	(4,014)	(138,944)	(7,409)
Loss from Ebenberg JV	(65,722)	0	(115,050)	0
Loss on extinguishment of debt	(689,621)	(4)	(4,259,987)	(536)	535
Total other (expense)	(755,343)	(1,266,560)	(4,836,879)	(1,462,259)
Net loss	(1,294,362)	(5,526,486)	(6,111,883)	(9,974,398)	(15,882,195)	(2,702,602)
Less net loss attributable to noncontrolling interest	(7,307)	(2,037,053)	(14,732)	(3,214,869)
Net income attributable to common stockholders	$ (1,287,055)	$ (3,489,433)	$ (6,097,151)	$ (6,759,529)
Net loss per common share - basic and diluted	$ 0	$ (0.01)	$ (0.02)	$ (0.02)
Weighted average number of common shares outstanding - basic and diluted	373,345,770	234,451,953	369,415,435	328,392,903
Amortization of debt discount					(4,629,089)	(303,942)
Amortization of debt discount, related party					0	(5,000)
Interest expense, related party					0	(76)
Loss from joint venture					(57,678)	0
Loss on settlement of debt					(536)	(186,954)
Total other (expense)					(4,869,997)	(503,381)
Net loss attributable:
Non-controlling interest					(2,580,925)	(216,686)
Common stockholders					$ (13,301,270)	$ (2,485,916)
Net loss per common share - basic and diluted			$ (0.02)	$ (0.02)	$ (0.05)	$ (0.01)
Weighted average number of common shares outstanding - basic and diluted			369,415,435	328,392,903	345,160,167	225,497,197

CONDENSED CONSOLIDATED STATEM_2

CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS DEFICIT (UNAUDITED) - USD ($)	Total	Series A, Preferred Stock	Common Stock	Additional Paid-In Capital	Noncontrolling Interest	Common Stock To Be Issued	Accumulated Deficit	Series B, Preferred Stock	Series B Preferreds Stock [Member]	Retained Earnings (Accumulated Deficit)	Series A Preferred Stocks [Member]
Balance, shares at Jun. 30, 2020		3,113,637	69,584,149
Balance, amount at Jun. 30, 2020	$ (31,224)	$ 31	$ 696	$ 379,971	$ 0	$ 372,397	$ (784,319)
Sale of common stock,share			16,308,334
Sale of common stock, amount	1,648,000	0	$ 163	1,599,837	0	48,000	0
Conversion of convertible notes and accrued interest,share			25,168,183
Conversion of convertible notes and accrued interest,amount	184,156	0	$ 252	183,904	0	0	0
Conversion of convertible notes and accrued interest	3,090	$ 0	$ 0	0	0	3,090	0
Conversion of Series A Preferred to Common Stock, shares		(44,367)	44,366,919
Conversion of Series A Preferred to Common Stock, amount	0	$ 0	$ 444	(444)	0	0	0
Cancellation of Series A Preferred shares issued in AAT merger, shares		(2,240,000)
Cancellation of Series A Preferred shares issued in AAT merger, amount		$ (22)	0	22	0	0	0
Cancellation of Series A Preferred shares issued for compensation in prior year, shares		(41,000)
Cancellation of Series A Preferred shares issued for compensation in prior year, amount		$ (1)	$ 0	1	0	0	0
Stock issued for services,share			24,540,909
Stock issued for services,amount	1,275,703	0	$ 245	1,275,458	0	0	0
Issuance of warrants with convertible notes	117,893	0	0	117,893	0	0	0
Issuance of warrants for advisory board services	38,332	0	0	38,332	0	0	0
Fair value of beneficial conversion feature associated with convertible debt	171,957	0	$ 0	171,957	0	0	0
Shares reclassed from common stock to be issued,share			112,847,466
Shares reclassed from common stock to be issued,amount	1	0	$ 1,128	371,270	0	(372,397)	0
Issuance of Series B Preferred Stock in connection with CEO's Employment Agreement, shares								1,000,000
Issuance of Series B Preferred Stock in connection with CEO's Employment Agreement, amount	3,090	0	0	(10)	0	0	0	$ 10
Net Loss	(2,702,602)	$ 0	$ 0	0	(216,686)	0	(2,485,916)
Exercise of warrants, amount	0
Balance, shares at Jun. 30, 2021		788,270	292,815,960					1,000,000	1,000,000		788,270
Balance, amounts at Jun. 30, 2021	705,306	$ 8	$ 2,928	4,138,191	(216,686)	51,090	(3,270,235)	$ 10	$ 10	$ (3,270,235)	$ 8
Sale of common stock,share			7,500,000
Sale of common stock, amount	1,668,500		$ 75	499,925		1,168,500
Issuance of common stock committed in prior period, shares			400,000
Issuance of common stock committed in prior period, amount			$ 4	47,996		(48,000)
Conversion of Series A Preferred to Common Stock, shares			4,000,000								(4,000)
Conversion of Series A Preferred to Common Stock, amount			$ 40	(40)
Shares issued as equity kicker, shares			250,000
Shares issued as equity kicker, amount	43,753		$ 3	43,750
Exercise of warrants, shares			4,185,000
Exercise of warrants, amount	128,550		$ 41	125,509		3,000
Stock issued for services,share			2,825,000
Stock issued for services,amount	541,100		$ 27	449,173		91,900
Conversion of convertible notes and accrued interest, shares			10,598,544
Conversion of convertible notes and accrued interest, amount	173,070		$ 106	176,054		(3,090)
Fair value of beneficial conversion feature associated with convertible debt	250,000			250,000
Stock option compensation	1,060,324			1,060,324
Net Loss	(4,447,915)				(1,177,816)					(3,270,099)
Balance, shares at Sep. 30, 2021			322,574,504						1,000,000		784,270
Balance, amounts at Sep. 30, 2021	122,688		$ 3,221	6,790,885	(1,394,502)	1,263,400			$ 10	(6,540,334)	$ 8
Balance, shares at Jun. 30, 2021		788,270	292,815,960					1,000,000	1,000,000		788,270
Balance, amount at Jun. 30, 2021	705,306	$ 8	$ 2,928	4,138,191	(216,686)	51,090	(3,270,235)	$ 10	$ 10	(3,270,235)	$ 8
Net Loss	(9,974,398)
Exercise of warrants, amount	128,550
Balance, shares at Dec. 31, 2021			358,202,770						1,000,000		781,132
Balance, amounts at Dec. 31, 2021	1,342,031		$ 3,577	14,451,855	(3,431,555)	347,900			$ 10	(10,029,764)	$ 8
Balance, shares at Jun. 30, 2021		788,270	292,815,960					1,000,000	1,000,000		788,270
Balance, amount at Jun. 30, 2021	705,306	$ 8	$ 2,928	4,138,191	(216,686)	51,090	(3,270,235)	$ 10	$ 10	(3,270,235)	$ 8
Sale of common stock,share			15,700,000
Sale of common stock, amount	2,078,500	0	$ 157	909,843	0	1,168,500	0
Conversion of convertible notes and accrued interest,share			14,828,244
Conversion of convertible notes and accrued interest,amount	426,819	$ 0	$ 148	429,761	0	(3,090)	0
Conversion of Series A Preferred to Common Stock, shares		(7,138)	7,138,000
Conversion of Series A Preferred to Common Stock, amount	0	$ 0	$ 71	(71)	0	0	0
Shares issued as equity kicker, shares			250,000
Shares issued as equity kicker, amount	43,753	0	$ 3	43,750	0	0	0
Stock issued for services,share			4,685,615
Stock issued for services,amount	761,954	0	$ 43	670,011	0	91,900	0
Fair value of beneficial conversion feature associated with convertible debt	2,615,419	0	0	2,615,419	0	0	0
Net Loss	(15,882,195)	0	$ 0	0	(2,580,925)	0	(13,301,270)
Issuance of common stock, shares			23,666,666
Issuance of common stock, amount	$ 0	0	$ 240	1,256,211	0	(1,256,450)	0
Exercise of warrants, shares	4,308,600		4,308,600
Exercise of warrants, amount	$ 128,550	0	$ 42	128,508	0	0	0
Inducement of conversion - interest expense, shares			845,936
Inducement of conversion - interest expense, amount	134,927	0	$ 8	134,918
Stock option compensation	3,248,181	0	0	3,248,181	0	0	0
Fair value of warrants associated with convertible debt	2,777,081	$ 0	$ 0	2,777,081	0	0	0
Balance, shares at Jun. 30, 2022		781,132	364,239,001					1,000,000	1,000,000		781,132
Balance, amounts at Jun. 30, 2022	(2,961,705)	$ 8	$ 3,637	16,351,806	(2,797,611)	51,950	(16,571,505)	$ 10	$ 10	(16,571,505)	$ 8
Balance, shares at Sep. 30, 2021			322,574,504						1,000,000		784,270
Balance, amount at Sep. 30, 2021	122,688		$ 3,221	6,790,885	(1,394,502)	1,263,400			$ 10	(6,540,334)	$ 8
Sale of common stock,share			8,200,000
Sale of common stock, amount	410,000		$ 82	409,918
Issuance of common stock committed in prior period, shares			23,266,666
Issuance of common stock committed in prior period, amount			$ 233	1,162,267		(1,162,500)
Conversion of convertible notes and accrued interest	250,000					250,000
Conversion of Series A Preferred to Common Stock, shares			3,138,000								(3,138)
Conversion of Series A Preferred to Common Stock, amount			$ 31	(31)
Exercise of warrants, shares			123,600
Exercise of warrants, amount			$ 1	2,999		(3,000)
Stock issued for services,share			900,000
Stock issued for services,amount	116,104		$ 9	116,095
Fair value of beneficial conversion feature associated with convertible debt	2,365,419			2,365,419
Stock option compensation	827,221			827,221
Net Loss	(5,526,486)				(2,037,053)					(3,489,430)
Fair value of warrants associated with convertible debt	2,777,081			2,777,081
Balance, shares at Dec. 31, 2021			358,202,770						1,000,000		781,132
Balance, amounts at Dec. 31, 2021	1,342,031		$ 3,577	14,451,855	(3,431,555)	347,900			$ 10	(10,029,764)	$ 8
Balance, shares at Jun. 30, 2022		781,132	364,239,001					1,000,000	1,000,000		781,132
Balance, amount at Jun. 30, 2022	(2,961,705)	$ 8	$ 3,637	16,351,806	(2,797,611)	51,950	(16,571,505)	$ 10	$ 10	(16,571,505)	$ 8
Conversion of Series A Preferred to Common Stock, shares			1,000,000								(1,000)
Conversion of Series A Preferred to Common Stock, amount			$ 10	(10)
Stock issued for services,share			457,143
Stock issued for services,amount	48,000		$ 5	47,995
Stock option compensation	306,170			306,170
Net Loss	(4,817,521)				(7,425)					(4,810,096)
Fair value of warrants associated with convertible debt	1,918,393			1,918,393
Adjustment for rounding			$ 5	(5)
Balance, shares at Sep. 30, 2022			366,696,144						1,000,000		780,132
Balance, amounts at Sep. 30, 2022	(5,506,663)		$ 3,657	18,624,349	(2,805,036)	51,950			$ 10	(21,381,601)	$ 8
Balance, shares at Jun. 30, 2022		781,132	364,239,001					1,000,000	1,000,000		781,132
Balance, amount at Jun. 30, 2022	(2,961,705)	$ 8	$ 3,637	16,351,806	(2,797,611)	51,950	$ (16,571,505)	$ 10	$ 10	(16,571,505)	$ 8
Net Loss	(6,111,883)
Exercise of warrants, amount	0
Balance, shares at Dec. 31, 2022			376,933,144						1,000,000		769,895
Balance, amounts at Dec. 31, 2022	(5,901,570)		$ 3,769	19,523,605	(2,812,343)	51,950			$ 10	(22,668,656)	$ 8
Balance, shares at Sep. 30, 2022			366,696,144						1,000,000		780,132
Balance, amount at Sep. 30, 2022	(5,506,663)		$ 3,657	18,624,349	(2,805,036)	51,950			$ 10	(21,381,601)	$ 8
Conversion of Series A Preferred to Common Stock, shares			10,237,000								(10,237)
Conversion of Series A Preferred to Common Stock, amount			$ 102	(102)
Stock option compensation	209,747			209,747
Net Loss	(1,294,362)				(7,307)					(1,287,055)
Fair value of warrants associated with convertible debt	689,621			689,621
Balance, shares at Dec. 31, 2022			376,933,144						1,000,000		769,895
Balance, amounts at Dec. 31, 2022	$ (5,901,570)		$ 3,769	$ 19,523,605	$ (2,812,343)	$ 51,950			$ 10	$ (22,668,656)	$ 8

CONDENSED CONSOLIDATED STATEM_3

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED) - USD ($)	6 Months Ended		12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Jun. 30, 2022	Jun. 30, 2021
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED)
Net Loss	$ (6,111,883)	$ 9,974,398	$ (15,882,195)	$ (2,702,602)
Cash Flows from Operating Activities
Depreciation and amortization	713	83	15,581	0
Stock option expense	515,917	1,887,545	3,248,181	1,275,703
Adjustments to reconcile net loss to net cash used by operating activities:
Stock issued for services	48,000	700,954	761,954	38,332
Loss on extinguishment of debt	4,259,987	0
Loss from joint venture investment	115,050	0
Amortization of debt discount	461,842	1,413,959	4,629,089	303,912
Operating lease right of use asset	22,103	19,899	40,867	(62)
Financing fees			178,680	0
Changes in operating assets & liabilities:
Lease liabilities	(23,575)	(20,498)	(42,643)	0
Loss from joint venture			57,678	0
Deposits and prepaids	(9,759)	(1,589)	478	113
Loss on settlement of debt			0	186,954
Accounts payable and accrued liabilities	(98,880)	(49,476)	(12,639)	(119,553)
Accrued liability, related party	42,000	5,000	(3,000)	0
Accrued Expenses		5,520	5,520	0
Net cash used by operating activities	(778,485)	(6,013,001)	(6,927,249)	(1,012,203)
Cash Flows from Investing Activities
Purchase of property and equipment	(2,567)	(4,990)	(19,990)	0
Net cash used in investing activities	(167,867)	(4,990)	(135,346)	0
Sale of common stock	0	2,078,500	2,078,500	1,648,000
Cash from exercise of warrants	0	128,550	128,550	0
Proceeds from convertible notes payable	0	4,958,950
Net cash provided by financing activities	0	7,166,000	7,166,000	1,935,850
Decrease in Cash	(946,352)	1,148,009	103,405	923,647
Cash at beginning of period	1,065,945	962,540	962,540	38,893
Cash at end of period	119,593	2,110,549	1,065,945	962,540
Cash paid for interest	0	0	0	0
Cash paid for income taxes	0	0	0	0
Conversion of convertible notes payable and accrued interest	0	437,246	440,995	187,246
Warrants issued with convertible notes payable	0	2,777,081	2,894,974	117,893
Beneficial conversion feature arising from convertible notes payable	0	2,615,419	2,615,419	171,597
Warrants issued with convertible notes payable extinguishment	$ 2,608,014	$ 0
Amortization of Debt Discount, Related Party			0	5,000
Shares to be issued			75,200	0
Cash Flows from Investing Activities
Investment in joint venture			(115,356)
Cash Flows from Financing Activities
Proceeds from convertible notes payable			$ 4,958,950	$ 287,850

ORGANIZATION AND NATURE OF BUSI

ORGANIZATION AND NATURE OF BUSINESS	6 Months Ended	12 Months Ended
	Dec. 31, 2022	Jun. 30, 2022
ORGANIZATION AND NATURE OF BUSINESS
ORGANIZATION AND NATURE OF BUSINESS	NOTE 1 - ORGANIZATION AND NATURE OF BUSINESS Company Overview Xeriant, Inc. (“Xeriant” or the “Company”) is dedicated to the acquisition, development and commercialization of transformative technologies, including eco-friendly specialty materials which can be successfully deployed and integrated across multiple industry sectors, and disruptive innovations related to the emerging aviation market called Advanced Air Mobility, which include next-generation aircraft. We seek to partner with and acquire strategic interests in visionary companies that accelerate this mission. The Company was incorporated in Nevada on December 18, 2009. On April 16, 2019, the Company entered into a Share Exchange Agreement with American Aviation Technologies, LLC (“AAT”), an aircraft design and development company focused on the emerging segment of the aviation industry of autonomous and semi-autonomous vertical take-off and landing (VTOL) unmanned aerial vehicles (UAVs). On September 30, 2019, the acquisition of AAT closed, and AAT became a subsidiary of the Company. On June 22, 2020, the name of the Company was changed to Xeriant, Inc. in the State of Nevada and subsequently approved by FINRA effective July 30, 2020 for the name and symbol change (XERI). On May 31, 2021, the Company entered into a Joint Venture Agreement with XTI Aircraft Company, to form a new company, called Eco-Aero, LLC, for purpose of completing the preliminary design of XTI’s TriFan 600, a 5-passenger plus pilot, hybrid electric, vertical takeoff and landing (eVTOL) fixed wing aircraft. Effective April 2, 2022 (the “Effective Date”) and Amended November 7, 2022, the Company entered into a Joint Venture Agreement (the “Joint Venture Agreement”) with Movychem s.r.o., a Slovakian limited liability company (“Movychem”) setting forth the terms for the establishment of a joint venture (the “Joint Venture”) to develop applications and commercialize Retacell ® Advanced Materials A primary focus of our Company is the acquisition and commercial exploitation of eco-friendly, advanced materials and chemicals which have applications across a broad range of industries and the potential to generate significant near-term revenue. The Company’s commercialization strategy encompasses licensing arrangements and joint ventures with major industry players, which would allow for more rapid access to the market with reduced capital requirements and financial risk. In addition to providing the production and distribution infrastructure, these established partnering companies can streamline testing and certification and add brand recognition value. The advanced materials and chemicals may be sold as standalone products, enhancements to existing products, or used in the development of proprietary products under a new trademarked brand owned by the Company. The Company is exploring manufacturing and branding opportunities for specific products derived from advanced materials and chemicals acquired or developed, which would involve setting up production facilities, equipment, systems and supply chain. Our plan to source and acquire strategic interests in visionary companies developing, integrating, and commercializing critical breakthrough technologies is underway with our first successful advanced materials transaction executed in the second quarter of 2022. Effective April 2, 2022, we entered into a Joint Venture Agreement with Movychem s.r.o, a Slovakian chemical ® ® ® ® ® On June 8, 2022, we announced the development of a multi-purpose, high-strength fire- and water-resistant composite panel made from a formulation of Movychem’s industrial flame-retardant, Retacell ® ® On August 12, 2022, we filed the trademark “NexBoard,” for construction panels, namely, composite sheets and panels composed primarily of plastic, reinforcement materials and fire-retardant chemicals for use in walls, ceilings, flooring, framing, siding, roofing and decking. The trademark filing was intentionally broad and based upon demand for a general all-purpose construction panel made from a mixture of fire-retardant and recycled materials. After experiencing supply chain issues, mechanical failures, and the general inability to produce an industrial-sized composite wall panels made with Retacell ® On March 31, 2023, we filed a provisional patent for unique composite sheets and panels composed primarily of plastic, reinforcement materials and fire-retardant chemicals for use in walls, ceilings, flooring, framing, siding, roofing and decking, used in construction. We are planning to build manufacturing facilities in the United States for the production of NexBoard in order to meet market demand. We have identified potential sites, received bids for specialized manufacturing equipment, developed timetables related to the action plan, and hired a managing director with decades of experience to oversee the projects. Aerospace Another area of interest for our Company is the emerging aviation market called Advanced Air Mobility (AAM), the transition to more efficient, eco-friendly, automated and convenient flight operations enabled by the convergence of technological advancements in design and engineering, composite materials, propulsion systems, battery energy density and manufacturing processes. Next-generation aircraft being developed for this market offer low-cost, on-demand flight for passengers and cargo, utilizing lower altitude airspace and bypassing the traditional hub and spoke airport network with vertical takeoff and landing (VTOL) capabilities. Many of these lightweight aircraft are electrically powered through either hybrid or pure battery systems, which allows for quieter, low emission flights over urban areas, however with limited speed and range. The adoption and integration of niche aerial services through AAM is expected to provide benefits throughout the economy. We plan to partner with and acquire strategic interests in visionary companies that accelerate our mission of commercializing critical breakthrough AAM technologies which enhance performance, increase safety, and enable and support more efficient, autonomous, and sustainable flight operations, including electric and hybrid-electric passenger and cargo transport aircraft capable of vertical takeoff and landing. Our plan to source and acquire strategic interests in leading aerospace companies developing breakthrough VTOL aircraft began in the second quarter of 2021. Effective May 27, 2021, we entered into a Joint Venture Agreement with XTI Aircraft Company (“XTI”), a privately owned OEM based in Englewood, Colorado for the purpose of completing the preliminary design of XTI’s TriFan 600, a 5-passenger plus pilot, hybrid electric vertical takeoff and landing (eVTOL) fixed-wing aircraft. Through our joint venture with XTI, (referred to hereinafter as the “XTI JV”), we were involved in the successful completion of the preliminary design of their TriFan 600 eVTOL aircraft. The TriFan 600 is being designed to become the fastest, longest-range VTOL aircraft in the world and the first commercial fixed-wing VTOL airplane, with current pre-orders exceeding $7 billion in gross revenues upon delivery of those aircraft. While the purpose of the XTI JV has been achieved, XTI and Xeriant continue to see value in the XTI JV for future collaboration in Advanced Ari Mobility. Should XTI and Xeriant determine it is in their best interest to terminate the XTI JV, then it will be dissolved. Should the XTI JV be dissolved, as of October 18, 2022, Xeriant would receive 5.5% equity ownership of XTI. Management believes that our holding and operating company structure has several advantages and will enable us to grow rapidly, acquiring assets primarily through acquisitions, joint ventures, strategic investments, and licensing arrangements. As a publicly traded company, we offer our subsidiaries such benefits as improved access to capital, higher valuations and lower risk through the shared ownership of a diversified portfolio, while allowing these entities to maintain independence in their distinct operations to focus on their fields of expertise. Cost savings and efficiencies may be realized from sharing non-operational functions such as finance, legal, tax, sales & marketing, human resources, purchasing power, as well as investor and public relations. Additionally, we are leveraging our relationship with Florida Atlantic University to provide a collaborative research arm for technologies that require additional validation and the backing of a respected research institution for credibility. The university also may provide access to various grants through the SBIR (Small Business Innovation Research), STTR (Small Business Technology Transfer, NSF (National Science Foundation) and other programs, and if warranted, introductions into a number of government agencies, such as DOD (Department of Defense) and DARPA (Defense Advanced Research Projects Agency). We are pursuing strategic alliances with companies that provide complementary technologies and access to new markets.	NOTE 1 - ORGANIZATION AND NATURE OF BUSINESS Xeriant, Inc. (“Xeriant” or the “Company”) is an aerospace company dedicated to the emerging aviation market called Advanced Air Mobility (AAM), the transition to eco-friendly, on demand flight, making air transportation more accessible and a greater part of our daily lives. Xeriant is focused on the acquisition, development, and proliferation of next generation hybrid-electric and fully electric aircraft with vertical takeoff and landing (eVTOL) capabilities, performance enhancing aerospace technologies and advanced materials, as well as critical support infrastructure. Xeriant is located at the Research Park at Florida Atlantic University in Boca Raton, Florida adjacent to the Boca Raton Airport, and trades on OTC Markets under the stock symbol, XERI. The Company was incorporated in Nevada on December 18, 2009. On April 16, 2019, the Company entered into a Share Exchange Agreement with American Aviation Technologies, LLC (“AAT”), an aircraft design and development company focused on the emerging segment of the aviation industry of autonomous and semi-autonomous vertical take-off and landing (VTOL) unmanned aerial vehicles (UAVs). On September 30, 2019, the acquisition of AAT closed, and AAT became a subsidiary of the Company. On June 22, 2020, the name of the Company was changed to Xeriant, Inc. in the State of Nevada and subsequently approved by FINRA effective July 30, 2020 for the name and symbol change (XERI). On May 31, 2021, the Company entered into a Joint Venture Agreement with XTI Aircraft Company, to form a new company, called Eco-Aero, LLC, for purpose of completing the preliminary design of XTI’s TriFan 600, a 5-passenger plus pilot, hybrid electric, vertical takeoff and landing (eVTOL) fixed wing aircraft. Effective April 2, 2022 (the “Effective Date”), the Company entered into a Joint Venture Agreement (the “Joint Venture Agreement”) with Movychem s.r.o., a Slovakian limited liability company (“Movychem”) setting forth the terms for the establishment of a joint venture (the “Joint Venture”) to develop applications and commercialize Retacell ®

SUMMARY OF SIGNIFICANT ACCOUNTI

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	6 Months Ended	12 Months Ended
	Dec. 31, 2022	Jun. 30, 2022
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	NOTE 2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Basis of Presentation The consolidated financial statements, which include the accounts of the Company, American Aviation Technologies, LLC, and Eco-Aero, LLC, its subsidiaries, are prepared in conformity with generally accepted accounting principles in the United States of America (U.S. GAAP). All significant intercompany balances and transactions have been eliminated. The consolidated financial statements, which include the accounts of the Company and its wholly owned subsidiaries, and related disclosures have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”). The Financial Statements have been prepared using the accrual basis of accounting in accordance with accounting principles generally accepted in the United States of America (“GAAP”) and presented in US dollars. The fiscal year end is June 30. Going Concern The Company's financial statements are prepared using the generally accepted accounting principles applicable to a going concern, which contemplates the realization of assets and liquidation of liabilities in the normal course of business. At December 31, 2022 and June 30, 2022, the Company had $119,593 and $1,065,945 in cash and $5,947,134 and $3,002,259 in negative working capital, respectively. For the six months ended December 31, 2022 and 2021, the Company had a net loss of $6,111,883 and $9,974,398, respectively. Continued losses may adversely affect the liquidity of the Company in the future. Therefore, the factors noted above raise substantial doubt about our ability to continue as a going concern. The recoverability of a major portion of the recorded asset amounts shown in the accompanying balance sheets is dependent upon continued operations of the Company, which in turn is dependent upon the Company's ability to raise additional capital, obtain financing and to succeed in its future operations. The financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern. The Company’s existence is dependent upon management’s ability to develop profitable operations and resolve its liquidity problems. Principles of Consolidation The consolidated financial statements include the accounts of Xeriant, Inc., American Aviation Technologies, LLC, and Eco-Aero, LLC. All significant intercompany balances and transactions have been eliminated. Use of Estimates The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. The most significant assumptions and estimates relate to the valuation of beneficial conversion features and warrants associated with convertible debt. Actual results could differ from these estimates. Fair Value Measurements and Fair Value of Financial Instruments The Company adopted ASC Topic 820, Fair Value Measurements. ASC Topic 820 clarifies the definition of fair value, prescribes methods for measuring fair value, and establishes a fair value hierarchy to classify the inputs used in measuring fair value as follows: Level 1: Inputs are unadjusted quoted prices in active markets for identical assets or liabilities available at the measurement date. Level 2: Inputs are unadjusted quoted prices for similar assets and liabilities in active markets, quoted prices for identical or similar assets and liabilities in markets that are not active, inputs other than quoted prices that are observable, and inputs derived from or corroborated by observable market data. Level 3: Inputs are unobservable inputs which reflect the reporting entity’s own assumptions on what assumptions the market participants would use in pricing the asset or liability based on the best available information. The estimated fair value of certain financial instruments, including all current liabilities are carried at historical cost basis, which approximates their fair values because of the short-term nature of these instruments. The inputs to the valuation methodology of stock options and warrants were under level 3 fair value measurements. Cash and Cash Equivalents For purposes of the Statements of Cash Flows, the Company considers highly liquid investments with an original maturity of three months or less to be cash equivalents. The Company has no cash equivalents. Convertible Debentures If the conversion features of conventional convertible debt provide for a rate of conversion that is below market value at issuance, this feature is characterized as a beneficial conversion feature (“BCF”). A BCF is recorded by the Company as a debt discount pursuant to ASC Topic 470-20 “Debt with Conversion and Other Options.” In those circumstances, the convertible debt is recorded net of the discount related to the BCF, and the Company amortizes the discount to interest expense, over the life of the debt. During the year ended June 30, 2022, the Company recorded a BCF in the amount of $2,615,419. Stock-based Compensation The Company measures the cost of employee services received in exchange for equity incentive awards based on the grant date fair value of the award. The Company uses the Black-Scholes valuation model to calculate the fair value of stock options granted to employees or consultants. Stock-based compensation expense is recognized over the period during which the employee is required to provide services in exchange for the award, which is usually the vesting period. Research and Development Expenses Expenditures for research and development are expensed as incurred. The Company incurred research and development expenses of $0 and $5,200,219 for the six months ended December 31, 2022 and 2021, respectively. Advertising and Marketing Expenses The Company expenses advertising and marketing costs as they are incurred. The Company recorded advertising expenses in the amount of $21,421 and $164,713 for the six months ended December 31, 2022 and 2021, respectively. Income Taxes The Company recognizes the effect of income tax positions only if those positions are more likely than not of being sustained. Recognized income tax positions are measured at the largest amount that is more likely than not of being realized. Changes in recognition or measurement are reflected in the period in which the change in judgment occurs. The Company records interest and penalties related to unrecognized tax benefits as a component of general and administrative expenses. Our consolidated federal tax return and any state tax returns are not currently under examination. The Company follows Accounting Standards Codification subtopic 740-10, Income Taxes (“ASC 740-10”) for recording the provision for income taxes. Deferred tax assets and liabilities are computed based upon the difference between the financial statement and income tax basis of assets and liabilities using the enacted marginal tax rate applicable when the related asset or liability is expected to be realized or settled. Deferred income tax expenses or benefits are based on the changes in the asset or liability during each period. If available evidence suggests that it is more likely than not that some portion or all of the deferred tax assets will not be realized, a valuation allowance is required to reduce the deferred tax assets to the amount that is more likely than not to be realized. Future changes in such valuation allowance are included in the provision for deferred income taxes in the period of change. Deferred income taxes may arise from temporary differences resulting from income and expense items reported for financial accounting and tax purposes in different periods. Basic Income (Loss) Per Share Under the provisions of ASC 260, “Earnings per Share,” basic loss per common share is computed by dividing net loss available to common shareholders by the weighted average number of shares of common stock outstanding for the periods presented. Diluted net loss per share reflects the potential dilution that could occur if securities or other contracts to issue common stock were exercised or converted into common stock or resulted in the issuance of common stock that would then share in the income of the Company, subject to anti-dilution limitations. The table below presents the computation of basic and diluted earnings per share for the six months ended December 31, 2022 and 2021: For the six months ended December 31, 2022 For the six months ended December 30, 2021 Numerator: Net loss $ (6,097,151 ) $ (6,759,529 ) Denominator: Weighted average common shares outstanding—basic 369,415,435 328,392,903 Dilutive common stock equivalents - - Weighted average common shares outstanding—diluted 369,415,435 328,392,903 Net loss per share: Basic $ (0.02 ) $ (0.02 ) Diluted $ (0.02 ) $ (0.02 )	NOTE 2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Basis of Presentation The consolidated financial statements, which include the accounts of the Company, American Aviation Technologies, LLC, and Eco-Aero, LLC, its subsidiaries, are prepared in conformity with generally accepted accounting principles in the United States of America (U.S. GAAP). All significant intercompany balances and transactions have been eliminated. The consolidated financial statements, which include the accounts of the Company and its wholly owned subsidiaries, and related disclosures have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”). The Financial Statements have been prepared using the accrual basis of accounting in accordance with accounting principles generally accepted in the United States of America (“GAAP”) and presented in US dollars. The fiscal year end is June 30. Going Concern The Company's financial statements are prepared using the generally accepted accounting principles applicable to a going concern, which contemplates the realization of assets and liquidation of liabilities in the normal course of business. At June 30, 2022 and 2021, the Company had $1,065,945 and $962,540 in cash and $3,002,259 in negative working capital and $677,257 in working capital, respectively. For the year ended June 30, 2022 and 2021, the Company had a net loss of $15,882,195 and $2,702,602, respectively. Continued losses may adversely affect the liquidity of the Company in the future. Therefore, the factors noted above raise substantial doubt about our ability to continue as a going concern. The recoverability of a major portion of the recorded asset amounts shown in the accompanying balance sheets is dependent upon continued operations of the Company, which in turn is dependent upon the Company's ability to raise additional capital, obtain financing and to succeed in its future operations. The financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern. The Company’s existence is dependent upon management’s ability to develop profitable operations and resolve its liquidity problems. Principles of Consolidation The consolidated financial statements include the accounts of Xeriant, Inc., American Aviation Technologies, LLC, and Eco-Aero, LLC. All significant intercompany balances and transactions have been eliminated. Use of Estimates The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. The most significant assumptions and estimates relate to the valuation of beneficial conversion features and warrants associated with convertible debt. Actual results could differ from these estimates. Fair Value Measurements and Fair Value of Financial Instruments The Company adopted ASC Topic 820, Fair Value Measurements. ASC Topic 820 clarifies the definition of fair value, prescribes methods for measuring fair value, and establishes a fair value hierarchy to classify the inputs used in measuring fair value as follows: Level 1: Inputs are unadjusted quoted prices in active markets for identical assets or liabilities available at the measurement date. Level 2: Inputs are unadjusted quoted prices for similar assets and liabilities in active markets, quoted prices for identical or similar assets and liabilities in markets that are not active, inputs other than quoted prices that are observable, and inputs derived from or corroborated by observable market data. Level 3: Inputs are unobservable inputs which reflect the reporting entity's own assumptions on what assumptions the market participants would use in pricing the asset or liability based on the best available information. The estimated fair value of certain financial instruments, including all current liabilities are carried at historical cost basis, which approximates their fair values because of the short-term nature of these instruments. The inputs to the valuation methodology of stock options and warrants were under level 3 fair value measurements. Cash and Cash Equivalents For purposes of the Statements of Cash Flows, the Company considers highly liquid investments with an original maturity of three months or less to be cash equivalents. The Company has no cash equivalents. Convertible Debentures If the conversion features of conventional convertible debt provide for a rate of conversion that is below market value at issuance, this feature is characterized as a beneficial conversion feature ("BCF"). A BCF is recorded by the Company as a debt discount pursuant to ASC Topic 470-20 "Debt with Conversion and Other Options." In those circumstances, the convertible debt is recorded net of the discount related to the BCF, and the Company amortizes the discount to interest expense, over the life of the debt. During the year ended June 30, 2022, the Company recorded a BCF in the amount of $2,615,419. Stock-based Compensation The Company measures the cost of employee services received in exchange for equity incentive awards based on the grant date fair value of the award. The Company uses the Black-Scholes valuation model to calculate the fair value of stock options granted to employees or consultants. Stock-based compensation expense is recognized over the period during which the employee is required to provide services in exchange for the award, which is usually the vesting period. Research and Development Expenses Expenditures for research and development are expensed as incurred. The Company incurred research and development expenses of $5,267,581 and $373,112 for the years ended June 30, 2022 and 2021, respectively. Advertising and Marketing Expenses The Company expenses advertising and marketing costs as they are incurred. The Company recorded advertising expenses in the amount of $651,567 and $1,047,120 for the years ended June 30, 2022 and 2021, respectively. Income Taxes The Company recognizes the effect of income tax positions only if those positions are more likely than not of being sustained. Recognized income tax positions are measured at the largest amount that is more likely than not of being realized. Changes in recognition or measurement are reflected in the period in which the change in judgment occurs. The Company records interest and penalties related to unrecognized tax benefits as a component of general and administrative expenses. Our consolidated federal tax return and any state tax returns are not currently under examination. The Company follows Accounting Standards Codification subtopic 740-10, Income Taxes ("ASC 740-10") for recording the provision for income taxes. Deferred tax assets and liabilities are computed based upon the difference between the financial statement and income tax basis of assets and liabilities using the enacted marginal tax rate applicable when the related asset or liability is expected to be realized or settled. Deferred income tax expenses or benefits are based on the changes in the asset or liability during each period. If available evidence suggests that it is more likely than not that some portion or all of the deferred tax assets will not be realized, a valuation allowance is required to reduce the deferred tax assets to the amount that is more likely than not to be realized. Future changes in such valuation allowance are included in the provision for deferred income taxes in the period of change. Deferred income taxes may arise from temporary differences resulting from income and expense items reported for financial accounting and tax purposes in different periods. Basic Income (Loss) Per Share Under the provisions of ASC 260, “Earnings per Share,” basic loss per common share is computed by dividing net loss available to common shareholders by the weighted average number of shares of common stock outstanding for the periods presented. Diluted net loss per share reflects the potential dilution that could occur if securities or other contracts to issue common stock were exercised or converted into common stock or resulted in the issuance of common stock that would then share in the income of the Company, subject to anti-dilution limitations. The table below presents the computation of basic and diluted earnings per share for the years ended June 30, 2022 and 2021: For the year ended June 30, 2022 For the year ended June 30, 2021 Numerator: Net loss $ (15,882,195 ) $ (2,702,602 ) Denominator: Weighted average common shares outstanding—basic 345,160,167 225,497,197 Dilutive common stock equivalents - - Weighted average common shares outstanding—diluted 345,160,167 225,497,197 Net loss per share: Basic $ (0.05 ) $ (0.01 ) Diluted $ (0.05 ) $ (0.01 )

JOINT VENTURE

JOINT VENTURE	6 Months Ended	12 Months Ended
	Dec. 31, 2022	Jun. 30, 2022
JOINT VENTURE
JOINT VENTURE	NOTE 3 – JOINT VENTURE JV with XTI Aircraft On May 31, 2021, the Company entered into a Joint Venture Agreement (the “Agreement”) with XTI Aircraft Company (“XTI”), a Delaware corporation, to form a new company, called Eco-Aero, LLC (the “JV”), a Delaware limited liability company, with the purpose of completing the preliminary design of XTI’s TriFan 600, a 5-passenger plus pilot, hybrid electric, vertical takeoff, and landing (eVTOL) fixed wing aircraft. Under the Agreement, Xeriant is contributing capital, technology, and strategic business relationships, and XTI is contributing intellectual property licensing rights and know-how. XTI and the Company each own 50 percent of the JV. The JV is managed by a management committee consisting of five members, three appointed by the Company and two by XTI. The Agreement was effective on June 4, 2021, with an initial deposit of $1 million into the JV. Xeriant’s financial commitment is for up to $10 million, contributed as required by the aircraft development timeline and budget. The Company analyzed the transaction under ASC 810 Consolidation The Company includes the assets and liabilities related to the VIE in the unaudited Condensed Consolidated Balance Sheets. Xeriant, Inc. provides cash to the VIE to fund its operations. The carrying amounts of consolidated VIE's assets and liabilities associated with the VIE subsidiary were as follows: December 31, 2022 June 30, 2022 Assets Cash $ 4,392 $ 4,516 Due to Xeriant Inc. $ 5,479,547 $ 5,479,547 Total Assets $ 5,483,939 $ 5,484,063 JV with Movychem On April 2, 2022 the Company entered into a Joint Venture Agreement with Movychem s.r.o., a Slovakian limited liability company setting forth the terms for the establishment of a joint venture (the “Joint Venture”) to develop applications and commercialize Retacell ® For its capital contribution to the Joint Venture, pursuant to a Patent and Exclusive License and Assignment Agreement (the “Patent Agreement”), Movychem is transferring to the Joint Venture all of its interest to the know-how and intellectual property relating to Retacell® exclusive of all of all patents, and the Company is contributing the amount of $2,600,000 payable (a) $600,000 at the rate of $25,000 per month over a 24 month period and (b) $2,000,000 within five business days of a closing of a financing in which the Company receives net proceeds of at least $3,000,000 but in no event later than six months from the Effective Date (Amended to February 15, 2023, as per Amended Agreement), should Movychem be in compliance with its obligations related to the Movychem JV. At such time as the Company makes its $2,000,000 payment (and assuming the Company is current with its then monthly capital contributions), pursuant to the Patent Agreement, Movychem will transfer all of its rights, title and interest to all of the patents related to Retacell ® ® Concurrently with the execution of the Joint Venture Agreement, the Joint Venture will provide to the Joint Venture technical services related to the exploitation of the Retacell ® ® Under the Joint Venture Agreement, the Company has agreed to grant to certain individuals affiliated with Movychem five-year warrants (the “Warrants”) to purchase an aggregate of 170,000,000 shares of the Company’s common stock at an exercise price of $0.01 per share with vesting depending on the satisfaction of various milestones as described therein. The Joint Venture Agreement grants to Movychem the right to dissolve the Joint Venture in the event that the Company fails to make any of its capital contributions in which case the Joint Venture will be required to grant back to Movychem all joint venture intellectual property and the assignment to Movychem of any outstanding licenses, should Movychem be in compliance with its obligations related to the Movychem JV. Additionally, the Services Agreement will be amended to provide that the 40% of royalties to be paid by to the Company will be limited to licensees who were first introduced to the Joint Venture or Movychem, as the case may be. The Company analyzed the transaction under ASC 810 Consolidation, to determine if the joint venture classifies as a Variable Interest Entity (“VIE”). The Joint Venture qualifies as a VIE based on the fact the JV does not have sufficient equity to operate without financial support from both parties. According to ASC 810-25-38, a reporting entity shall consolidate a VIE when that reporting entity has a variable interest (or combination of variable interests) that provides the reporting entity with a controlling financial interest on the basis of the provisions in paragraphs 810-10-25-38A through 25-38J. The reporting entity that consolidates a VIE is called the primary beneficiary of that VIE. According to the JV operating agreement, the ownership interests are 50/50 and the agreement provides for a Management Committee of five members. Two of the five members are from Xeriant and Movychem, respectively and one is appointed by mutual agreement of the parties. Movychem is transferring to the Joint Venture all of its interest to the know-how and intellectual property relating to Retacell ® As of December 31, 2022 and June 30, 2022, the Company contributed $280,656 and $115,356 to the joint venture, respectively. For the six months ended December 31, 2022 the Company contributed $165,300 to the joint venture.	NOTE 3 – JOINT VENTURE JV with XTI Aircraft On May 31, 2021, the Company entered into a Joint Venture Agreement (the “Agreement”) with XTI Aircraft Company (“XTI”), a Delaware corporation, to form a new company, called Eco-Aero, LLC (the “JV”), a Delaware limited liability company, with the purpose of completing the preliminary design of XTI’s TriFan 600, a 5-passenger plus pilot, hybrid electric, vertical takeoff, and landing (eVTOL) fixed wing aircraft. Under the Agreement, Xeriant is contributing capital, technology, and strategic business relationships, and XTI is contributing intellectual property licensing rights and know-how. XTI and the Company each own 50 percent of the JV. The JV is managed by a management committee consisting of five members, three appointed by the Company and two by XTI. The Agreement was effective on June 4, 2021, with an initial deposit of $1 million into the JV. Xeriant’s financial commitment is for up to $10 million, contributed as required by the aircraft development timeline and budget. The Company analyzed the transaction under ASC 810 Consolidation JV with Movychem On April 2, 2022 the Company entered into a Joint Venture Agreement with Movychem s.r.o., a Slovakian limited liability company setting forth the terms for the establishment of a joint venture (the “Joint Venture”) to develop applications and commercialize Retacell ® For its capital contribution to the Joint Venture, pursuant to a Patent and Exclusive License and Assignment Agreement (the “Patent Agreement”), Movychem is transferring to the Joint Venture all of its interest to the know-how and intellectual property relating to Retacell ® ® ® Concurrently with the execution of the Joint Venture Agreement, Xeriant will provide to the Joint Venture technical services related to the exploitation of the Retacell ® ® Under the Joint Venture Agreement, the Company has agreed to grant to certain individuals affiliated with Movychem five-year warrants (the “Warrants”) to purchase an aggregate of 170,000,000 shares of the Company’s common stock at an exercise price of $0.01 per share with vesting depending on the satisfaction of various milestones as described therein. The Joint Venture Agreement grants to Movychem the right to dissolve the Joint Venture in the event that the Company fails to make any of its capital contributions in which case the Joint Venture will be required to grant back to Movychem all joint venture intellectual property and the assignment to Movychem of any outstanding licenses, should Movychem be in compliance with its obligations related to the Movychem JV. Additionally, the Services Agreement will be amended to provide that the 40% of royalties to be paid by to the Company will be limited to licensees who were first introduced to the Joint Venture or Movychem, as the case may be. The Company analyzed the transaction under ASC 810 Consolidation, to determine if the joint venture classifies as a Variable Interest Entity (“VIE”). The Joint Venture qualifies as a VIE based on the fact the JV does not have sufficient equity to operate without financial support from both parties. According to ASC 810-25-38, a reporting entity shall consolidate a VIE when that reporting entity has a variable interest (or combination of variable interests) that provides the reporting entity with a controlling financial interest on the basis of the provisions in paragraphs 810-10-25-38A through 25-38J. The reporting entity that consolidates a VIE is called the primary beneficiary of that VIE. According to the JV operating agreement, the ownership interests are 50/50 and the agreement provides for a Management Committee of five members. Two of the five members are from Xeriant and Movychem, respectively and one is appointed by mutual agreement of the parties. Movychem is transferring to the Joint Venture all of its interest to the know-how and intellectual property relating to Retacell ® As of June 30, 2022, the Company contributed $115,356 to the joint venture.

CONCENTRATION OF CREDIT RISKS

CONCENTRATION OF CREDIT RISKS	6 Months Ended	12 Months Ended
	Dec. 31, 2022	Jun. 30, 2022
CONCENTRATION OF CREDIT RISKS
CONCENTRATION OF CREDIT RISKS	NOTE 4 – CONCENTRATION OF CREDIT RISKS The Company maintains accounts with financial institutions. All cash in checking accounts is non-interest bearing and is fully insured by the Federal Deposit Insurance Corporation (FDIC). At times, cash balances may exceed the maximum coverage provided by the FDIC on insured depositor accounts. The Company believes it mitigates its risk by depositing its cash and cash equivalents with major financial institutions. On December 31, 2022 and June 30, 2022, the Company had $0 and $811,429 in excess of FDIC insurance, respectively.	NOTE 4 – CONCENTRATION OF CREDIT RISKS The Company maintains accounts with financial institutions. All cash in checking accounts is non-interest bearing and is fully insured by the Federal Deposit Insurance Corporation (FDIC). At times, cash balances may exceed the maximum coverage provided by the FDIC on insured depositor accounts. The Company believes it mitigates its risk by depositing its cash and cash equivalents with major financial institutions. On June 30, 2022, the Company had $811,429 in excess of FDIC insurance.

OPERATING LEASE RIGHT OF USE AS

OPERATING LEASE RIGHT OF USE ASSET AND OPERATING LEASE LIABILITY	6 Months Ended	12 Months Ended
	Dec. 31, 2022	Jun. 30, 2022
OPERATING LEASE RIGHT OF USE ASSET AND OPERATING LEASE LIABILITY
OPERATING LEASE RIGHT-OF-USE ASSET AND OPERATING LEASE LIABILITY	NOTE 5 – OPERATING LEASE RIGHT-OF-USE ASSET AND OPERATING LEASE LIABILITY The Company leases 2,911 square feet of office space located in the Research Park at Florida Atlantic University, Innovation Centre 1, 3998 FAU Boulevard, Suite 309, Boca Raton, Florida. The Company entered into a lease agreement commencing on November 1, 2019 through January 1, 2025 in which the first three months of rent were abated. Due to the COVID-19 pandemic, the company decided to have all employees work from home and intends to build out the office space by the end of June 2023 to allow employees to work from the office in July of 2023. The following table illustrates the base rent amounts over the term of the lease: Base Rent Periods November 1, 2019 to October 31, 2020 $ 4,367 November 1, 2020 to October 31, 2021 $ 4,498 November 1, 2021 to October 31, 2022 $ 4,633 November 1, 2022 to October 31, 2023 $ 4,772 November 1, 2023 to October 31, 2024 $ 4,915 November 1, 2024 to January 31, 2025 $ 5,063 Operating lease right-of-use asset and liability are recognized at the present value of the future lease payments at the lease commencement date. The interest rate used to determine the present value is our incremental borrowing rate, estimated to be 10%, as the interest rate implicit in most of our leases is not readily determinable. Operating lease expense is recognized on a straight-line basis over the lease term. Since the common area maintenance expenses are expenses that do not depend on an index or rate, they are excluded from the measurement of the lease liability and recognized in other general and administrative expenses on the statements of operations. At inception the Company paid prepaid rent in the amount of $4,659, which was netted against the operating lease right-of-use asset balance until it was applied in February 2020. Right-of-use asset is summarized below: December 31, 2022 Office lease $ 220,448 Less: accumulated amortization (114,209 ) Right -of- use asset, net $ 106,239 Operating lease liability is summarized below: December 31, 2022 Office lease $ 117,585 Less: current portion (50,647 ) Long term portion 66,938 Maturity of the lease liability is as follows: Fiscal year ending June 30, 2023 30,491 Fiscal year ending June 30, 2024 62,201 Fiscal year ending June 30, 2025 37,112 129,803 Present value discount (12,218 ) Lease liability $ 117,585	NOTE 5 – OPERATING LEASE RIGHT-OF-USE ASSET AND OPERATING LEASE LIABILITY The Company leases 2,911 square feet of office space located in the Research Park at Florida Atlantic University, Innovation Centre 1, 3998 FAU Boulevard, Suite 309, Boca Raton, Florida. The Company entered into a lease agreement commencing on November 1, 2019 through January 1, 2025 in which the first three months of rent were abated. Due to the COVID-19 pandemic, the company decided to have all employees work from home and intends to build out the office space by the end of 2022 to allow employees to work from the office in January of 2023. The following table illustrates the base rent amounts over the term of the lease: Base Rent Periods November 1, 2019 to October 31, 2020 $ 4,367 November 1, 2020 to October 31, 2021 $ 4,498 November 1, 2021 to October 31, 2022 $ 4,633 November 1, 2022 to October 31, 2023 $ 4,772 November 1, 2023 to October 31, 2024 $ 4,915 November 1, 2024 to January 31, 2025 $ 5,063 Operating lease right-of-use asset and liability are recognized at the present value of the future lease payments at the lease commencement date. The interest rate used to determine the present value is our incremental borrowing rate, estimated to be 10%, as the interest rate implicit in most of our leases is not readily determinable. Operating lease expense is recognized on a straight-line basis over the lease term. Since the common area maintenance expenses are expenses that do not depend on an index or rate, they are excluded from the measurement of the lease liability and recognized in other general and administrative expenses on the statements of operations. At inception the Company paid prepaid rent in the amount of $4,659, which was netted against the operating lease right-of-use asset balance until it was applied in February 2020. Right-of-use asset is summarized below: June 30, 2022 Office lease $ 220,448 Less: accumulated amortization (92,106 ) Right -of- use asset, net $ 128,342 Operating lease liability is summarized below: June 30, 2022 Office lease $ 141,160 Less: current portion (48,963 ) Long term portion 92,197 Maturity of the lease liability is as follows: Fiscal year ending June 30, 2023 60,392 Fiscal year ending June 30, 2024 62,201 Fiscal year ending June 30, 2025 37,112 159,705 Present value discount (18,545 ) Lease liability $ 141,160

EXCHANGE AGREEMENT

EXCHANGE AGREEMENT	12 Months Ended
	Jun. 30, 2022
EXCHANGE AGREEMENT
NOTE 6 - EXCHANGE AGREEMENT	NOTE 6 – EXCHANGE AGREEMENT On April 16, 2019, the Company and the members of American Aviation Technologies, LLC (“AAT”) entered into a Share Exchange Agreement (“Agreement”). The agreement, which became effective on September 30, 2019, was pursuant to which the Company acquired 100% of the issued and outstanding membership units in exchange for the issuance of shares of the Company’s Series A Preferred Stock constituting 86.39% of the total voting power of the Company’s capital stock to be outstanding upon closing, after giving effect to the consummation of concurrent debt settlement and other capital stock issuances but before the issuance of shares of capital stock for investor relations purposes. As a result of the Exchange Agreement, AAT became a subsidiary of the Company. On September 30, 2019 just prior to the exchange, the Company issued 170,000 shares of preferred stock as compensation and 193,637 shares of preferred stock in satisfaction of $2,608,224 in liabilities.

CONVERTIBLE NOTES PAYABLE

CONVERTIBLE NOTES PAYABLE	6 Months Ended	12 Months Ended
	Dec. 31, 2022	Jun. 30, 2022
CONVERTIBLE NOTES PAYABLE
CONVERTIBLE NOTES PAYABLE	NOTE 6 – CONVERTIBLE NOTES PAYABLE The carrying value of convertible notes payable, net of discount, as of December 31, 2022 and June 30, 2022 was $5,850,000 and $3,936,185, respectively. December 31, June 30, Convertible Notes Payable 2022 2022 Convertible notes payable issued October 27, 2021 (0% interest) – Auctus Fund LLC $ 5,850,000 $ 6,050,000 Total face value 5,850,000 6,050,000 Less unamortized discount - (2,113,815 ) Carrying value $ 5,850,000 $ 3,936,185 Between September 27, 2019 and August 10, 2021, the Company issued convertible notes payable with an aggregate face value of $892,300, of which $342,950 were issued by our subsidiary AAT. The notes have a coupon rate of 6% and maturity dates between three and six months. The agreements provided the holder has the option to convert the principal balance and any accrued interest to common stock of the Company. In the event the holder does not elect to convert the note prior to maturity, the note will automatically convert to common stock. Of the $892,300, $342,950 is convertible at $.0033 per share, $87,000 is convertible at $0.025 per share, $180,550 is convertible at $.03 per share, $31,800 is convertible at $0.003 per share, and the remaining $250,000 is convertible at $.06 per share. All these convertible notes payable have been converted as of December 31, 2021. During the six months ended December 31, 2021, the Company recorded amortization of debt discount related to these notes in the amount of $1,413,959 and interest expense of $4,014. Auctus Fund, LLC Senior Secured Note On October 27, 2021, the Company issued a convertible note payable with Auctus Fund, LLC (the “Auctus Note”) with the principal sum of $6,050,000, which amount is the $5,142,500 actual amount of the purchase price, hereof plus an original issue discount in the amount of $907,500 and to pay interest on the unpaid principal amount hereof at the rate of zero percent per annum from the issue date until the note becomes due and payable, and $433,550 for professional fees in completing the transactions. The note has a maturity date of twelve months. The agreement provides the holder has the option to convert the principal balance and any accrued interest to common stock of the Company at a conversion price of lesser of (i) $0.1187 or (ii) 75% of the offering price per share divided by the number of shares of common stock. The Auctus Note is secured by the grant of a first priority security interest in the assets of the Company. In connection with the notes, the Company issued warrants indexed to an aggregate 50,968,828 shares of common stock. The warrants have a term of five years and an exercise price of $0.1187. The warrants were recorded at fair value of $2,777,081 to additional-paid-in-capital in accordance with ASC 815-10 based upon the allocation of the debt proceeds. The Company estimated the fair value of the warrants using a Black-Scholes option-pricing model, which is based, in part, upon subjective assumptions including but not limited to stock price volatility, the expected life of the warrants, the risk-free interest rate and the fair value of the common stock underlying the warrants. The Company estimates the volatility of its stock based on the average of three similar size public companies peer group historical volatility that is in line with the expected remaining life of the warrants. The risk-free interest rate is based on the U.S. Treasury zero-coupon bond for a maturity similar to the expected remaining life of the warrants. The expected remaining life of the warrants is assumed to be equivalent to their remaining contractual term. The Company was required to determine if the debt contained a beneficial conversion feature (“BCF”), which is based on the intrinsic value on the date of issuance. The Company recorded $2,365,419 conversion feature in additional paid-in capital. The BCF resulted in a debt discount and are amortized over the life of the note. Effective July 26, 2022, the Company entered into an Amendment to Senior Secured Promissory Note (the “Amendment”) with Auctus Fund, LLC (“Auctus”) pursuant to which the parties agreed to amend the Company’s Senior Secured Convertible Promissory Note in the principal amount of $6,050,000 dated October 27, 2021 (the “Note”) issued to Auctus. The Amendment (i) extended the maturity date of the Note to November 1, 2022 and (ii) extended the dates for the completion of the acquisition of XTI Aircraft and the uplist of the Company’s common stock to a national securities exchange to November 1, 2022. In consideration of the Amendment, the Company agreed to (i) grant to Auctus a new Warrant to purchase 25,000,000 shares of Common Stock dated July 26, 2022 (the “Warrant”) at an exercise price of $0.09 per share; (ii) make a prepayment of the Note in the amount of $100,000; and (iii) cause a director of the Company to cancel his 10b-5(1) Plan. The Company tested the modification under ASC 470-50-40 to determine if the modification resulted in an extinguishment. It was determined the present value of the cash flows under the terms of the new debt instrument was at least 10 percent different from the present value of the remaining cash flows under the terms of the original instrument. As a result, the modification resulted in a loss on an extinguishment in the amount of $3,570,366. The loss on extinguishment was determined as follows: Reacquisition Price: Modified convertible debt instrument 5,950,000 Fair value of warrants 1,918,393 Cash payment 100,000 Carrying Value of Original Instrument Original convertible debt instrument 6,050,000 Debt discount - warrant (707,585 ) Original issue discount (341,692 ) Debt discount - BCF (602,696 ) Carrying value of original debt 4,398,027 Loss on extinguishment 3,570,366 Effective December 27, 2022, the Company entered into an Amendment to Senior Secured Promissory Note (the “Amendment”) with Auctus Fund, LLC (“Auctus”) pursuant to which the parties agreed to amend the Company’s Senior Secured Convertible Promissory Note in the principal amount of $6,050,000 dated October 27, 2021 (the “Note”) issued to Auctus. The Amendment (i) extended the maturity date of the Note to March 15, 2023 and (ii) extended the dates for the completion of the acquisition of XTI Aircraft and the uplist of the Company’s common stock to a national securities exchange to March 15, 2023. In consideration of the Amendment, the Company agreed to (i) grant to Auctus a new Warrant to purchase 25,000,000 shares of Common Stock dated December 27, 2022 (the “Warrant”) at an exercise price of $0.09 per share; and (ii) make a prepayment of the Note in the amount of $50,000 on January 15, 2023 and $50,000 on February 15, 2023. The Company tested the modification under ASC 470-50-40 to determine if the modification resulted in an extinguishment. It was determined the present value of the cash flows under the terms of the new debt instrument was at least 10 percent different from the present value of the remaining cash flows under the terms of the original instrument. As a result, the modification resulted in a loss on an extinguishment in the amount of $689,621. The loss on extinguishment was determined as follows: Reacquisition Price: Modified convertible debt instrument 5,850,000 Fair value of warrants 689,621 Accrued Short-term Liability 100,000 Carrying Value of Original Instrument Carrying value of original debt 5,950,000 Loss on extinguishment 689,621 For the six months ended December 31, 2022, the Company recorded $461,482 in amortization of debt discount related to the Auctus note. As of December 31, 2022 and June 30, 2022, the carrying value of the Auctus note was $5,850,000 and $3,936,185, respectively.	NOTE 7 – CONVERTIBLE NOTES PAYABLE The carrying value of convertible notes payable, net of discount, as of June 30, 2022 and 2021 was $3,936,185 and $158,196, respectively. June 30, June 30, Convertible Notes Payable 2022 2021 Convertible notes payable issued January 5, 2021 (6% interest) $ - $ 25,000 Convertible notes payable issued January 11, 2021 (6% interest) - 142,550 Convertible notes payable issued August 9, 2021 (6% interest) - - Convertible notes payable issued August 10, 2021 (6% interest) - - Convertible notes payable issued October 27, 2021 (0% interest) – Auctus Fund LLC 6,050,000 - Total face value 6,050,000 167,550 Less unamortized discount (2,113,815 ) (9,354 ) Carrying value $ 3,936,185 $ 158,196 Between September 27, 2019 and August 10, 2021, the Company issued convertible notes payable with an aggregate face value of $892,300, of which $342,950 were issued by our subsidiary AAT. The notes have a coupon rate of 6% and maturity dates between three and six months. The agreements provided the holder has the option to convert the principal balance and any accrued interest to common stock of the Company. In the event the holder does not elect to convert the note prior to maturity, the note will automatically convert to common stock. Of the $892,300, $342,950 is convertible at $.0033 per share, $87,000 is convertible at $0.025 per share, $180,550 is convertible at $.03 per share, $31,800 is convertible at $0.003 per share, and the remaining $250,000 is convertible at $.06 per share. All these convertible notes payable have been converted as of June 30, 2022 and $167,550 principal balance remaining as of June 30, 2021. The Company evaluated the agreement under ASC 815 Derivatives and Hedging (“ASC 815”). ASC 815 generally requires the analysis embedded terms and features that have characteristics of derivatives to be evaluated for bifurcation and separate accounting in instances where their economic risks and characteristics are not clearly and closely related to the risks of the host contract. None of the embedded terms required bifurcation and liability classification. However, the Company was required to determine if the debt contained a beneficial conversion feature (“BCF”), which is based on the intrinsic value on the date of issuance. In connection with the notes, the Company issued warrants indexed to an aggregate 8,848,333 shares of common stock. The warrants have a term of two years and an exercise price of $.025. The Company evaluated the warrants under ASC 815 Derivatives and Hedging (“ASC 815”) and determined that they did not require liability classification. The warrants were recorded in additional paid-in capital under their aggregate relative fair value of $156,225. Auctus Fund, LLC Senior Secured Note On October 27, 2021, the Company issued a convertible note payable with Auctus Fund, LLC (the “Auctus Note”) with the principal sum of $6,050,000, which amount is the $5,142,500 actual amount of the purchase price, hereof plus an original issue discount in the amount of $907,500 and to pay interest on the unpaid principal amount hereof at the rate of zero percent per annum from the issue date until the note becomes due and payable, and $433,550 for professional fees in completing the transactions. The note currently has a maturity date of February 15, 2023. The agreement provides the holder has the option to convert the principal balance and any accrued interest to common stock of the Company at a conversion price of lesser of (i) $0.1187 or (ii) 75% of the offering price per share divided by the number of shares of common stock. The Auctus Note is secured by the grant of a first priority security interest in the assets of the Company. In connection with the notes, the Company issued warrants indexed to an aggregate 50,968,828 shares of common stock. The warrants have a term of five years and an exercise price of $0.1187. The warrants were recorded at fair value of $2,777,081 to additional-paid-in-capital in accordance with ASC 815-10 based upon the allocation of the debt proceeds. The Company estimated the fair value of the warrants using a Black-Scholes option-pricing model, which is based, in part, upon subjective assumptions including but not limited to stock price volatility, the expected life of the warrants, the risk-free interest rate and the fair value of the common stock underlying the warrants. The Company estimates the volatility of its stock based on the average of three similar size public companies peer group historical volatility that is in line with the expected remaining life of the warrants. The risk-free interest rate is based on the U.S. Treasury zero-coupon bond for a maturity similar to the expected remaining life of the warrants. The expected remaining life of the warrants is assumed to be equivalent to their remaining contractual term. The Company was required to determine if the debt contained a beneficial conversion feature (“BCF”), which is based on the intrinsic value on the date of issuance. The Company recorded $2,365,419 conversion feature in additional paid-in capital. The BCF resulted in a debt discount and are amortized over the life of the note. The Company is in communication with Auctus Fund, LLC and is actively working on strategies to extinguish, extend or restructure the Senior Secured Promissory Note. No assurance can be made as to the results of such actions. For the year ended June 30, 2022 and 2021, the Company recorded $4,629,089 and $303,942 in amortization of debt discount related to the notes. For the year ended June 30, 2022 and 2021, the Company recorded $138,943 and $7,409 in interest expense related to the notes, respectively. The balance of this note as of June 30, 2022 was $3,936,185.

RELATED PARTY TRANSACTIONS

RELATED PARTY TRANSACTIONS	6 Months Ended	12 Months Ended
	Dec. 31, 2022	Jun. 30, 2022
RELATED PARTY TRANSACTIONS
RELATED PARTY TRANSACTIONS	NOTE 7– RELATED PARTY TRANSACTIONS Consulting fees During the six months ended December 31, 2022 and 2021, the Company recorded $100,000 and $74,000 respectively, in consulting fees to Ancient Investments, LLC, a Company owned by the Company’s CEO, Keith Duffy and the Company’s Executive Director of Corporate Operations, Scott Duffy. As of December 31, 2022, and June 30, 2022, $15,000 and $22,000 was recorded in accrued liabilities. For the six months ended December 31, 2022 and 2021, the Company recorded $52,000 and $52,000 respectively, in consulting fees to Edward DeFeudis, a Director of the Company. As of December 31, 2022, and June 30, 2022, $10,000 and $0 was recorded in accrued liabilities. During the six months ended December 31, 2022 and 2021, the Company recorded $35,000 and $37,000 respectively, in consulting fees to AMP Web Services, a Company owned by the Company’s CTO, Pablo Lavigna. As of December 31, 2022 and June 30, 2022, $7,000 and $7,000 was recorded in accrued liabilities. During the six months ended December 31, 2022 and 2021, the Company recorded $15,000 and $15,000 respectively, in consulting fees to Keystone Business Development Partners, a Company owned by the Company’s CFO, Brian Carey.	NOTE 8 – RELATED PARTY TRANSACTIONS Consulting fees During the years ended June 30, 2022 and 2021, the Company recorded $184,000 and $98,000 respectively, in consulting fees to Ancient Investments, LLC, a Company owned by the Company’s CEO, Keith Duffy and the Company’s Executive Director of Corporate Operations, Scott Duffy. As of June 30, 2022 and June 30, 2021, $15,000 and $0 was recorded in accrued liabilities. For the years ended June 30, 2022 and 2021, the Company recorded $122,000 and $40,000 respectively, in consulting fees to Edward DeFeudis, a Director of the Company. During the years ended June 30, 2022 and 2021, the Company recorded $86,000 and $49,500 respectively, in consulting fees to AMP Web Services, a Company owned by the Company’s CIO, Pablo Lavigna. On August 26, 2020, the Company issued 4,090,909 shares of common stock for payment of $13,500 for services performed in May, June and July 2020. As of June 30, 2022 and June 30, 2021, $7,000 and $0 was recorded in accrued liabilities. During the years ended June 30, 2022 and 2021, the Company recorded $40,425 and $20,000 respectively, in consulting fees to Keystone Business Development Partners, a Company owned by the Company’s CFO, Brian Carey. As of June 30, 2022 and June 30, 2021, $0 and $30,000 was recorded in accrued liabilities.

COMMITMENTS AND CONTINGENCIES

COMMITMENTS AND CONTINGENCIES	6 Months Ended	12 Months Ended
	Dec. 31, 2022	Jun. 30, 2022
COMMITMENTS AND CONTINGENCIES
COMMITMENTS AND CONTINGENCIES	NOTE 8 – COMMITMENTS AND CONTINGENCIES During the normal course of business, the Company may be exposed to litigation. When the Company becomes aware of potential litigation, it evaluates the merits of the case in accordance with FASB ASC 450-20-50, Contingencies Joint Venture In connection with the Eco-Aero, LLC Joint Venture, discussed in Note 3, the Company has the right to invest up to $10,000,000 into the joint venture. Financial Advisory Agreements On August 10, 2021, the Company entered into an Advisory Agreement with an outside firm to assist the Company with fundraising activities. In connection with the agreement, the Company has the following commitments: · to issue 500,000 shares payable at the date of the agreement, 500,000 shares payable three months from the date of the agreement, 500,000 shares payable nine months from the date of the agreement. · Pay a financing fee of 1.5% of gross proceeds received by the Company up to $100,000,000; a financing fee of 1.25% of gross proceeds received by the Company from $100,000,000-$200,000,000, and a financing fee of 1% of gross proceeds received by the Company over $200,000,000 · M&A fee of 1.5% of the value of a business or asset sold up to $50,000,000; an M&A fee of 1.25% of value of a business or asset sold from $50,000,000-$100,000,000, an M&A fee of 1% of value of a business or asset sold from $100,000,000-$200,000,000, and an M&A fee of 0.5% of value of a business or asset sold over $200,000,000 During the year ended June 30, 2022, the Company issued all 1,500,000 shares under the agreement. On August 19, 2021, the Company entered into an Advisory Agreement with an outside firm to assist the Company with fundraising activities. In connection with the agreement, the Company has the following commitments: · Issue 2,225,000 common shares payable at the date of the agreement, and 2,225,000 common shares payable upon an uplisting of the Company’s common stock to a national exchange. · Pay a cash fee of seven percent 7% of the amount of capital raised, invested or committed; and deliver a warrant (the “Agent Warrant”) to purchase shares of the Common Stock equal to seven percent (7%) of the number of shares of Common Stock underlying the securities issued in the Financing. · Pay a cash fee for entering into a transaction including, without limitation, a merger, acquisition or sale of stock or assets equal to one- and one-half percent (1.5%), or in the event a transaction is consummated with a party that was in communication with the Company prior to the date of this contract, then the fee shall equal one half percent (0.5%). During the year ended June 30, 2022, the Company issued the initial 2,225,000 shares. Litigation On September 1, 2021, Xeriant Inc. brought a cause of action in the Southern District of Florida against a former shareholder for claims, including but not limited to, breach of contract, misrepresentation, and asserting claims to recoup monetary and in-kind distributions made to the shareholder by the Company. The defendant submitted an affirmative defense and counterclaim on October 29, 2021. Board of Advisors Agreements The Company has entered into advisor agreements with various advisory board members. The agreements provide for the following: On October 27, 2020, the Company agreed to issue 300,000 common shares immediately, 2-year cashless warrants to purchase 300,000 common shares at the current price, and $2,500 per meeting paid 50% in cash and 50% in common shares. On January 18, 2021, the Company agreed to issue 50,000 common shares, two-year cashless warrants to purchase 25,000 common shares at the current price, and $2,500 per meeting paid in cash, common shares, or a combination. On January 22, 2021, the Company agreed to issue 50,000 common shares, two-year cashless warrants to purchase 25,000 common shares at the current price, and $2,500 per meeting paid in cash, common shares, or a combination. On March 7, 2021 the Company paid an advisor $2,500 and issued 50,000 common shares. On July 1, 2021, the Company agreed to issue 100,000 common shares, and $2,500 per meeting paid in cash, common shares, or a combination, an additional bonus of $25,000 paid in common shares issued at the end of each year of service, an option to purchase 5,000,000 common shares at $0.12 per share, vesting quarterly over 24 months, and for each of the following three years (beginning July 1, 2022), an option to purchase an additional 1,000,000 common shares per year thereafter at a 25% discount to the average market price for the preceding 10 trading days. On July 6, 2021, provided an option to purchase 5,000,000 common shares at $0.12 per share, vesting quarterly over 24 months, a bonus of 250,000 common shares issued upon a strategic partnership with a major airline, $2,500 per formal meeting paid in common shares, and an additional bonus of $25,000 paid in common shares issued at the end of each year of service. On July 28, 2021, the Company agreed to issue 250,000 common shares immediately, an option to purchase 5,000,000 common shares at $0.12 per share, vesting quarterly over 24 months, a bonus of 5,000,000 common shares for bringing in a strategic partner that significantly strengthens the Company’s market position, $2,500 per formal meeting paid in cash, common shares or a combination, and an additional bonus of $25,000 paid in common shares issued at the end of each year of service On August 9, 2021, the Company agreed to issue 50,000 common shares, $2,500 per meeting paid in cash, common shares, or a combination, and an additional bonus of $25,000 paid in common shares issued at the end of each year of service. On August 20, 2021, the Company agreed to issue 100,000 common shares, and $2,500 per meeting paid in cash, common shares, or a combination, an additional bonus of $25,000 paid in common shares issued at the end of each year of service, an option to purchase 4,000,000 common shares at $0.12 per share, vesting quarterly over 24 months. On January 20, 2022, the Company agreed to issue 250,000 common shares, and $5,000 paid on a monthly basis, for a period of three months, and an option to purchase 2,250,000 common shares at $0.12 per share, vesting immediately. On March 28, 2022, the Company agreed to issue 150,000 common shares vested monthly over one year, and $2,500 per meeting paid in cash, and additional bonus of $25,000 paid in common shares issued at the end of each year of service.	NOTE 9 – COMMITMENTS AND CONTINGENCIES During the normal course of business, the Company may be exposed to litigation. When the Company becomes aware of potential litigation, it evaluates the merits of the case in accordance with FASB ASC 450-20-50, Contingencies Joint Venture In connection with the Eco-Aero, LLC Joint Venture, discussed in Note 3, the Company has the right to invest up to $10,000,000 into the joint venture. Financial Advisory Agreements On August 10, 2021, the Company entered into an Advisory Agreement with an outside firm to assist the Company with fundraising activities. In connection with the agreement, the Company has the following commitments: · to issue 500,000 shares payable at the date of the agreement, 500,000 shares payable three months from the date of the agreement, 500,000 shares payable nine months from the date of the agreement. · Pay a financing fee of 1.5% of gross proceeds received by the Company up to $100,000,000; a financing fee of 1.25% of gross proceeds received by the Company from $100,000,000-$200,000,000, and a financing fee of 1% of gross proceeds received by the Company over $200,000,000 · M&A fee of 1.5% of the value of a business or asset sold up to $50,000,000; an M&A fee of 1.25% of value of a business or asset sold from $50,000,000-$100,000,000, an M&A fee of 1% of value of a business or asset sold from $100,000,000-$200,000,000, and an M&A fee of 0.5% of value of a business or asset sold over $200,000,000 During the year ended June 30, 2022, the Company issued all 1,500,000 shares under the agreement. On August 19, 2021, the Company entered into an Advisory Agreement with an outside firm to assist the Company with fundraising activities. In connection with the agreement, the Company has the following commitments: · Issue 2,225,000 common shares payable at the date of the agreement, and 2,225,000 common shares payable upon an uplisting of the Company’s common stock to a national exchange. · Pay a cash fee of seven percent 7% of the amount of capital raised, invested or committed; and deliver a warrant (the “Agent Warrant”) to purchase shares of the Common Stock equal to seven percent (7%) of the number of shares of Common Stock underlying the securities issued in the Financing. · Pay a cash fee for entering into a transaction including, without limitation, a merger, acquisition or sale of stock or assets equal to one- and one-half percent (1.5%), or in the event a transaction is consummated with a party that was in communication with the Company prior to the date of this contract, then the fee shall equal one half percent (0.5%). During the year ended June 30, 2022, the Company issued the initial 2,225,000 shares. Litigation On September 1, 2021, Xeriant Inc. brought a cause of action in the Southern District of Florida against a former shareholder for claims, including but not limited to, breach of contract, misrepresentation, and asserting claims to recoup monetary and in-kind distributions made to the shareholder by the Company. The defendant submitted an affirmative defense and counterclaim on October 29, 2021. Board of Advisors Agreements The Company has entered into advisor agreements with various advisory board members. The agreements provide for the following: On October 27, 2020, the Company agreed to issue 300,000 common shares immediately, 2-year cashless warrants to purchase 300,000 common shares at the current price, and $2,500 per meeting paid 50% in cash and 50% in common shares. On January 18, 2021, the Company agreed to issue 50,000 common shares, two-year cashless warrants to purchase 25,000 common shares at the current price, and $2,500 per meeting paid in cash, common shares, or a combination. On January 22, 2021, the Company agreed to issue 50,000 common shares, two-year cashless warrants to purchase 25,000 common shares at the current price, and $2,500 per meeting paid in cash, common shares, or a combination. On March 7, 2021 the Company paid an advisor $2,500 and issued 50,000 common shares. On July 1, 2021, the Company agreed to issue 100,000 common shares, and $2,500 per meeting paid in cash, common shares, or a combination, an additional bonus of $25,000 paid in common shares issued at the end of each year of service, an option to purchase 5,000,000 common shares at $0.12 per share, vesting quarterly over 24 months, and for each of the following three years (beginning July 1, 2022), an option to purchase an additional 1,000,000 common shares per year thereafter at a 25% discount to the average market price for the preceding 10 trading days. On July 6, 2021, provided an option to purchase 5,000,000 common shares at $0.12 per share, vesting quarterly over 24 months, a bonus of 250,000 common shares issued upon a strategic partnership with a major airline, $2,500 per formal meeting paid in common shares, and an additional bonus of $25,000 paid in common shares issued at the end of each year of service. On July 28, 2021, the Company agreed to issue 250,000 common shares immediately, an option to purchase 5,000,000 common shares at $0.12 per share, vesting quarterly over 24 months, a bonus of 5,000,000 common shares for bringing in a strategic partner that significantly strengthens the Company’s market position, $2,500 per formal meeting paid in cash, common shares or a combination, and an additional bonus of $25,000 paid in common shares issued at the end of each year of service On August 9, 2021, the Company agreed to issue 50,000 common shares, $2,500 per meeting paid in cash, common shares, or a combination, and an additional bonus of $25,000 paid in common shares issued at the end of each year of service. On August 20, 2021, the Company agreed to issue 100,000 common shares, and $2,500 per meeting paid in cash, common shares, or a combination, an additional bonus of $25,000 paid in common shares issued at the end of each year of service, an option to purchase 4,000,000 common shares at $0.12 per share, vesting quarterly over 24 months. On January 20, 2022, the Company agreed to issue 250,000 common shares, and $5,000 paid on a monthly basis, for a period of three months, and an option to purchase 2,250,000 common shares at $0.12 per share, vesting immediately. On March 28, 2022, the Company agreed to issue 150,000 common shares vested monthly over one year, and $2,500 per meeting paid in cash, and additional bonus of $25,000 paid in common shares issued at the end of each year of service.

EQUITY

EQUITY	6 Months Ended	12 Months Ended
	Dec. 31, 2022	Jun. 30, 2022
EQUITY
EQUITY	NOTE 9 – EQUITY Common Stock As of December 31, 2022 and June 30, 2022, the Company had 5,000,000,000 shares of common stock authorized with a par value of $0.00001. There were 376,933,144 and 365,239,001 shares issued and outstanding as of December 31, 2022 and June 30, 2022, respectively. Fiscal Year 2022 Issuances During the year ended June 30, 2022 in connection with one of the subscription agreements, the Company issued 250,000 shares as an equity kicker valued at $43,753, which has been expensed as a financing costs. During the year ended June 30, 2022, the Company issued 4,308,600 shares of common stock as a result of warrant exercises in the aggregate proceeds of $128,550. During the year ended June 30, 2022, the Company issued 4,685,615 shares of common stock for services, valued at $761,954. During the year ended June 30, 2022, the Company sold 39,366,666 shares of common stock for aggregate proceeds of $2,078,500. During the year ended June 30, 2022, the Company issued 7,138,000 shares of common stock in exchange for the conversion of 7,138 shares of Series A Preferred Stock. During the year ended June 30, 2022, the Company issued 10,598,544 shares of common stock for the conversion of $167,550 in principal and $4,985 in accrued interest. This resulted in a loss on extinguishment of debt in the amount of $535. During the year ended June 30, 2022, the Company issued 4,229,680 shares of common stock for the conversion of $250,000 principal balance of convertible notes payable and $3,749 accrued interest. During the year ended June 30, 2022, the Company issued 845,936 shares of common stock in exchange for the inducement to the convertible notes holders to convert at fair value of $134,927. Six Months Ended December 31, 2022 On July 11, 2022, the Company issued 1,000,000 shares of common stock in exchange for the conversion of 1,000 shares of Series A Preferred Stock. On July 13, 2022, the Company issued 457,143 shares to a consultant for services valued at $48,000. On October 24, 2022, the Company issued 10,237,000 shares of common stock in exchange for the conversion of 10,237 shares of Series A Preferred Stock. Common Stock to be Issued During the year ended June 30, 2022, the Company sold 200,000 shares of common stock for aggregate proceeds of $6,000, or $0.03 per share. As of June 30, 2022, these shares are categorized in common stock to be issued. During the year ended June 30, 2022, the Company agreed to pay a consultant 250,000 shares in exchange to $45,950 in services. As of June 30, 2022, these shares are categorized in common stock to be issued. Series A Preferred Stock There are 100,000,000 shares authorized as preferred stock, of which 3,500,000 are designated as Series A Preferred Stock having a par value of $0.00001 per share. The Series A preferred stock has the following rights: · Voting: The preferred shares shall be entitled to 100 votes to every one share of common stock. · Dividends: The Series A Preferred Stockholders are treated the same as the Common Stock holders except at the dividend on each share of Series A Convertible Preferred Stock is equal to the amount of the dividend declared and paid on each share of Common Stock multiplied by the Conversion Rate. · Conversion: Each share of Series A Preferred Stock is convertible, at the option of the holder thereof, at any time into shares of Common Stock on a 1:1,000 basis. · The shares of Series A Preferred Stock are redeemable at the option of the Corporation at any time after September 30, 2022 upon not less than 30 days written notice to the holders. It is not mandatorily redeemable. As of December 31, 2022, and June 30, 2022, the Company has 769,895 and 781,132 of shares of Series A Preferred Stock issued and outstanding, respectively. On February 15, 2021, in accordance with Florida Law and conversations with counsel, the Board of Directors of the Company rescinded 990,000 Series A Preferred Shares, which represented all preferred shares issued to one of the shareholders in the Share Exchange between American Aviation Technologies, LLC and Xeriant, Inc. entered into on April 19, 2019, due to breach of contract. During March of 2021, the remaining former members of American Aviation Technologies, LLC agreed to allow the Company to rescind an aggregate of 1,250,001 of their 1,760,000 Series A Preferred Shares issued pursuant to the Share Exchange between American Aviation Technologies, LLC and Xeriant, Inc., as a result of said breach. As a result of the cancellation, the Company reduced the investment in AAT by the value of these preferred shares. On March 27, 2021, Spider Investments, LLC returned 41,000 Series A Preferred Shares to the treasury of the Company. On July 11,2022, the Company issued 1,000,000 shares of common stock in exchange for the conversion of 1,000 shares of Series A Preferred Stock. On October 24, 2022, the Company issued 10,237,000 shares of common stock in exchange for the conversion of 10,237 shares of Series A Preferred Stock. Series B Preferred Stock On March 25, 2021, the Certificate of Designation for the Series B Preferred was recorded by the State of Nevada. There are 100,000,000 shares authorized as preferred stock, of which 1,000,000 are designated as Series B Preferred Stock having a par value of $0.00001 per share. The Series B preferred stock is not convertible, does not have any voting rights and no liquidation preference. During the year ended June 30, 2021, the Company issued 1,000,000 shares of Series B Preferred Stock to the Company’s CEO as part of his employment agreement. Stock Options In connection with certain advisory board compensation agreements, the Company issued an aggregate 21,250,000 options at an exercise price of $0.12 per share for the year ended June 30, 2022. These options vest quarterly over twenty-four months and have a term of three years. The grant date fair value was $3,964,207. The Company recorded compensation expense in the amount of $515,917 and $1,887,545 for these options for the six months ended December 31, 2022 and 2021, respectively. As of December 31, 2022, there was $186,199 of total unrecognized compensation cost related to non-vested portion of options granted. As of December 31, 2022, there are 21,250,000 options outstanding, of which 15,375,000 are exercisable. The weighted average remaining term is 1.38 years. Significant inputs and results arising from the Black-Scholes process are as follows for the options: Quoted market price on valuation date $ 0.169 - $0.23 Exercise prices $ 0.12 Range of expected term 1.55 Years – 2.49 Years Range of market volatility: Range of equivalent volatility 215.12% - 275.73 % Range of interest rates 0.20% - 0.47 % Warrants As of December 31, 2022 and June 30, 2022, the Company had 105,512,161 and 55,512,161 warrants outstanding respectively. The warrants were issued in connection with the Convertible Notes (See Note 6). The warrants have a term of two to five years and an exercise price range from $0.1187 to $0.025. The Company evaluated the warrants under ASC 815 Derivatives and Hedging (“ASC 815”) and determined that they did not require liability classification. The warrants were recorded in additional paid-in capital under their aggregate relative fair value of $2,777,081. During the year ended June 30, 2022, holders of warrants exercised warrants for 4,305,000 shares of common stock for aggregate proceeds of $128,550. As of December 31, 2022 and June 30, 2022, the weighted average remaining useful life of the warrants was 4.0.	NOTE 10 – EQUITY Common Stock As of June 30, 2022 and June 30, 2021, the Company had 5,000,000,000 shares of common stock authorized with a par value of $0.00001. There were 365,239,001 and 292,815,960 shares issued and outstanding as of June 30, 2022 and June 30, 2021, respectively. Fiscal Year 2021 Issuances On July 30, 2020, the Company issued 16,011,818 shares of common stock related to conversions of debt from the previous fiscal year, which were previously recorded in common stock to be issued. On August 26, 2020, the Company issued 4,090,909 shares of common stock for payment of $13,500 for services performed in May, June and July 2020. The shares were valued at $200,454 or $0.049 per share. As of result the Company recorded a loss on settlement in debt in the amount of $186,954. On September 8, 2020, the Company issued 96,835,648 shares of common stock related to conversions of debt from the previous fiscal year, which were previously recorded in common stock to be issued. On October 30, 2020, the Company issued 300,000 shares of common stock to an advisory board member for services. The shares were valued at $13,200 or $0.044 per share. On November 17, 2020, the Company sold 1,700,000 shares of common for $25,500, or $0.015 per share. On November 24, 2020, the Company sold 1,700,000 shares of common for $25,500, or $0.015 per share. On December 1, 2020, the Company issued 2,000,000 shares of common stock for investment relation services valued at $100,000, or $0.05 per share. On December 1, 2020, the Company issued 18,000,000 shares of common stock for investment relation services valued at $900,000, or $0.05 per share. On January 29, 2021, the Company issued 50,000 shares of common stock to an advisory board member for services. The shares were valued at $25,500 or $0.51 per share. On February 9, 2021, the Company issued 19,595,442 shares of common stock for the conversion of $127,150 in principal and $2,709 in accrued interest. In March of 2021, the Company sold 12,075,001 shares of common for $1,497,000, or $0.12 per share. On March 22, 2021, the Company issued 50,000 shares of common stock to an advisory board member for services. The shares were valued at $13,800 or $0.28 per share. On March 22, 2021, the Company issued 50,000 shares of common stock to an advisory board member for services. The shares were valued at $22,750 or $0.46 per share. On March 22, 2021, the Company issued 4,557,943 shares of common stock for the conversion of $23,000 in principal and $853 in accrued interest. On April 26, 2021, the Company issued 1,014,798 shares of common stock for the conversion of $30,000 in principal and $444 in accrued interest. On May 7, 2021, the Company sold 833,333 shares of common for $100,000, or $0.12 per share. During the year ended June 30, 2021, certain holders of preferred stock converted 44,367 shares into 44,366,919 shares of common stock. Fiscal Year 2022 Issuances During the year ended June 30, 2022 in connection with one of the subscription agreements, the Company issued 250,000 shares as an equity kicker valued at $43,753, which has been expensed as a financing costs. During the year ended June 30, 2022, the Company issued 4,308,600 shares of common stock as a result of warrant exercises in the aggregate proceeds of $128,550. During the year ended June 30, 2022, the Company issued 4,685,615 shares of common stock for services, valued at $761,954. During the year ended June 30, 2022, the Company sold 39,366,666 shares of common stock for aggregate proceeds of $2,078,500. During the year ended June 30, 2022, the Company issued 7,138,000 shares of common stock in exchange for the conversion of 7,138 shares of Series A Preferred Stock. During the year ended June 30, 2022, the Company issued 10,598,544 shares of common stock for the conversion of $167,550 in principal and $4,985 in accrued interest. This resulted in a loss on extinguishment of debt in the amount of $535. During the year ended June 30, 2022, the Company issued 4,229,680 shares of common stock for the conversion of $250,000 principal balance of convertible notes payable and $3,749 accrued interest. During the year ended June 30, 2022, the Company issued 845,936 shares of common stock in exchange for the inducement to the convertible notes holders to convert at fair value of $134,927. Common Stock to be Issued During the year ended June 30, 2022, the Company sold 200,000 shares of common stock for aggregate proceeds of $6,000, or $0.03 per share. As of June 30, 2022, these shares are categorized in common stock to be issued. During the year ended June 30, 2022, the Company agreed to pay a consultant 250,000 shares in exchange to $45,950 in services. As of June 30, 2022, these shares are categorized in common stock to be issued. Series A Preferred Stock There are 100,000,000 shares authorized as preferred stock, of which 3,500,000 are designated as Series A Preferred Stock having a par value of $0.00001 per share. The Series A preferred stock has the following rights: · Voting · Dividends: · Conversion · The shares of Series A Preferred Stock are redeemable at the option of the Corporation at any time after December 31, 2022 upon not less than 30 days written notice to the holders. It is not mandatorily redeemable. As of June 30, 2022 and 2021, the Company has 781,132 and 788,270 shares of Series A Preferred Stock issued and outstanding, respectively. On February 15, 2021, in accordance with Florida Law and conversations with counsel, the Board of Directors of the Company rescinded 990,000 Series A Preferred Shares, which represented all preferred shares issued to one of the shareholders in the Share Exchange between American Aviation Technologies, LLC and Xeriant, Inc. entered into on April 19, 2019, due to breach of contract. During March of 2021, the remaining former members of American Aviation Technologies, LLC agreed to allow the Company to rescind an aggregate of 1,250,001 of their 1,760,000 Series A Preferred Shares issued pursuant to the Share Exchange between American Aviation Technologies, LLC and Xeriant, Inc., as a result of said breach. As a result of the cancellation, the Company reduced the investment in AAT by the value of these preferred shares. On March 27, 2021, Spider Investments, LLC returned 41,000 Series A Preferred Shares to the treasury of the Company. Series B Preferred Stock On March 25, 2021, the Certificate of Designation for the Series B Preferred was recorded by the State of Nevada. There are 100,000,000 shares authorized as preferred stock, of which 1,000,000 are designated as Series B Preferred Stock having a par value of $0.00001 per share. The Series B preferred stock is not convertible, does not have any voting rights and no liquidation preference. During the year ended June 30, 2021, the Company issued 1,000,000 shares of Series B Preferred Stock to the Company’s CEO as part of his employment agreement.

NON-CONTROLLING INTEREST

NON-CONTROLLING INTEREST	6 Months Ended	12 Months Ended
	Dec. 31, 2022	Jun. 30, 2022
NON-CONTROLLING INTEREST
NON-CONTROLLING INTEREST	NOTE 10 - NON-CONTROLLING INTEREST AAT membership unit adjustment On May 12, 2021, on further advice of counsel and in good faith , AAT Subsidiary On May 12, 2021, the Company’s position in American Aviation Technologies, LLC was reduced to 64%, and therefore the subsidiary is now classified as majority owned.	NOTE 11 - NON-CONTROLLING INTEREST AAT membership unit adjustment On May 12, 2021, on further advice of counsel and in good faith , AAT Subsidiary On May 12, 2021, the Company’s position in American Aviation Technologies, LLC was reduced to 64%, and therefore the subsidiary is now classified as majority owned. Stock Options In connection with certain advisory board compensation agreements, the Company issued an aggregate 21,250,000 options at an exercise price of $0.12 per share for the year ended June 30, 2022. These options vest quarterly over twenty-four months and have a term of three years. The grant date fair value was $3,964,207. The Company recorded compensation expense in the amount of $3,248,181 for these options for the year ended June 30, 2022. As of June 30, 2022, there was $702,166 of total unrecognized compensation cost related to non-vested portion of options granted. As of June 30, 2022, there are 21,250,000 options outstanding, of which 9,375,000 are exercisable. The weighted average remaining term is 2.1 years. A summary of the Company’s stock options activity is as follows: Number of Options Weighted- Average Exercise Price Weighted- Average Contractual Term (in years) Aggregate Intrinsic Value Outstanding at June 30, 2021 - $ - Granted 21,250,000 0.12 Exercised - - Canceled - - Outstanding at June 30, 2022 21,250,000 $ 0.12 2.1 $ - Exercisable at June 30, 2022 9,375,000 $ 0.12 2.1 $ - Significant inputs and results arising from the Black-Scholes process are as follows for the options: Quoted market price on valuation date $0.169 - $0.23 Exercise prices $0.12 Range of expected term 1.55 Years – 2.49 Years Range of market volatility: Range of equivalent volatility 215.12% - 275.73% Range of interest rates 0.20% - 0.47% Warrants As of June 30, 2022 and June 30, 2021, the Company had 55,512,161 and 8,848,333 warrants outstanding, respectively. The warrants were issued in connection with the Convertible Notes (See Note 6). The warrants have a term of two to five years and an exercise price range from $0.1187 to $.025. The Company evaluated the warrants under ASC 815 Derivatives and Hedging (“ASC 815”) and determined that they did not require liability classification. The warrants were recorded in additional paid-in capital under their aggregate relative fair value of $2,777,081. During the year ended June 30, 2022, holders of warrants exercised warrants for 4,305,000 shares of common stock for aggregate proceeds of $128,550. As of June 30, 2022, the weighted average remaining useful life of the warrants was 4.0. A summary of the Company’s stock warrants activity is as follows: Number of Warrants Weighted- Average Exercise Price Weighted- Average Contractual Term (in years) Aggregate Intrinsic Value Outstanding at June 30, 2021 8,848,333 $ 0.03 0.94 - Granted 50,968,828 0.1187 4.6 - Exercised (4,305,000 ) - Canceled - - Outstanding at June 30, 2022 55,512,161 $ 0.111 4.0 $ - Vested and expected to vest at June 30, 2022 55,512,161 $ 0.111 4.0 $ - Exercisable at June 30, 2022 55,512,161 $ 0.111 4.0 $ -

INCOME TAXES

INCOME TAXES	12 Months Ended
	Jun. 30, 2022
INCOME TAXES
INCOME TAXES	NOTE 12 – INCOME TAXES The Company accounts for income taxes in accordance with the provisions of FASB ASC 740, Accounting for Uncertainty in Income Taxes. At June 30, 2022 and 2021, the significant components of the deferred tax assets are summarized below: 2022 2021 Deferred income tax asset Net operating loss carryforwards $ 5,860,409 3,237,960 Book to tax differences in intangible assets - Total deferred income tax asset 5,860,409 3,237,960 Less: valuation allowance (5,860,409 ) (3,237,960 ) Total deferred income tax asset $ — $ — The Company periodically evaluates the likelihood of the realization of deferred tax assets and adjusts the carrying amount of the deferred tax assets by the valuation allowance to the extent the future realization of the deferred tax assets is not judged to be more likely than not. The Company considers many factors when assessing the likelihood of future realization of its deferred tax assets, including its recent cumulative earnings experience by taxing jurisdiction, expectations of future taxable income or loss, the carryforward periods available to the Company for tax reporting purposes, and other relevant factors. Future changes in the unrecognized tax benefit will have no impact on the effective tax rate due to the existence of the valuation allowance. The Company estimates that the unrecognized tax benefit will not change significantly within the next twelve months. The Company will continue to classify income tax penalties and interest as part of general and administrative expense in its consolidated statements of operations. There were no interest or penalties accrued as of June 30, 2022.

SUBSEQUENT EVENTS

SUBSEQUENT EVENTS	6 Months Ended	12 Months Ended
	Dec. 31, 2022	Jun. 30, 2022
SUBSEQUENT EVENTS
SUBSEQUENT EVENTS	NOTE 11 – SUBSEQUENT EVENTS Subsequent to December 31, 2022 and up to the date of this filing, the Company issued five 10 percent convertible notes totaling $130,000. These notes are convertible into the Company’s common shares at a 25 percent discount to the prospective IPO share price. In conjunction with these notes, the Company issued 1,300,000 5-year warrants to the Company’s purchase common shares at $0.09 per share. An S-1 Registration Statement was filed on January 18, 2023, for the purpose of raising capital for the Company to execute its business plan.	NOTE 13 – SUBSEQUENT EVENTS Effective August 1, 2022, the Company entered into an Amendment to Senior Secured Promissory Note (the “First Amendment”) with Auctus Fund, LLC (“Auctus”) pursuant to which the parties agreed to amend the Company’s Senior Secured Convertible Promissory Note in the principal amount of $6,050,000 dated October 27, 2021 (the “Note”) issued to Auctus. The Amendment (i) extended the maturity date of the Note to November 1, 2022 and (ii) extended the dates for the completion of the acquisition of XTI Aircraft and the uplist of the Company’s common stock to a national securities exchange to November 1, 2022. In consideration of the Amendment, the Company agreed to (i) grant to Auctus a new Warrant to purchase 25,000,000 shares of Common Stock dated July 26, 2022 (the “Warrant”) at an exercise price of $0.09 per share; (ii) make a prepayment of the Note in the amount of $100,000; and (iii) cause a director of the Company to cancel his 10b-5(1) Plan. Effective November 9 ,2022, the Company entered into a second amendment pursuant to which the maturity date was extended to the earliest to occur of the an uplist to the Nasdaq Stock market or February 15, 2023. In consideration of the new amendment, the Company agreed to grant to Auctus a new warrant to purchase 25,000,000 shares and make a prepayment of $25,000 within three business days from the effective date of the amendment and three additional prepayments of $25,000 on December 1, 2022, January 3, 2022 and February 1, 2023. In July 2022, the Company issued 1,000,000 shares of common stock in exchange for the conversion of 1,000 shares of Series A Preferred Stock. In July 2022, the Company issued 457,143 shares to a consultant for services.

SUMMARY OF SIGNIFICANT ACCOUN_2

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)	6 Months Ended	12 Months Ended
	Dec. 31, 2022	Jun. 30, 2022
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
Basis of Presentation	The consolidated financial statements, which include the accounts of the Company, American Aviation Technologies, LLC, and Eco-Aero, LLC, its subsidiaries, are prepared in conformity with generally accepted accounting principles in the United States of America (U.S. GAAP). All significant intercompany balances and transactions have been eliminated. The consolidated financial statements, which include the accounts of the Company and its wholly owned subsidiaries, and related disclosures have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”). The Financial Statements have been prepared using the accrual basis of accounting in accordance with accounting principles generally accepted in the United States of America (“GAAP”) and presented in US dollars. The fiscal year end is June 30. Going Concern The Company's financial statements are prepared using the generally accepted accounting principles applicable to a going concern, which contemplates the realization of assets and liquidation of liabilities in the normal course of business. At December 31, 2022 and June 30, 2022, the Company had $119,593 and $1,065,945 in cash and $5,947,134 and $3,002,259 in negative working capital, respectively. For the six months ended December 31, 2022 and 2021, the Company had a net loss of $6,111,883 and $9,974,398, respectively. Continued losses may adversely affect the liquidity of the Company in the future. Therefore, the factors noted above raise substantial doubt about our ability to continue as a going concern. The recoverability of a major portion of the recorded asset amounts shown in the accompanying balance sheets is dependent upon continued operations of the Company, which in turn is dependent upon the Company's ability to raise additional capital, obtain financing and to succeed in its future operations. The financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern. The Company’s existence is dependent upon management’s ability to develop profitable operations and resolve its liquidity problems.	The consolidated financial statements, which include the accounts of the Company, American Aviation Technologies, LLC, and Eco-Aero, LLC, its subsidiaries, are prepared in conformity with generally accepted accounting principles in the United States of America (U.S. GAAP). All significant intercompany balances and transactions have been eliminated. The consolidated financial statements, which include the accounts of the Company and its wholly owned subsidiaries, and related disclosures have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”). The Financial Statements have been prepared using the accrual basis of accounting in accordance with accounting principles generally accepted in the United States of America (“GAAP”) and presented in US dollars. The fiscal year end is June 30.
Going concern	The Company's financial statements are prepared using the generally accepted accounting principles applicable to a going concern, which contemplates the realization of assets and liquidation of liabilities in the normal course of business. At December 31, 2022 and June 30, 2022, the Company had $119,593 and $1,065,945 in cash and $5,947,134 and $3,002,259 in negative working capital, respectively. For the six months ended December 31, 2022 and 2021, the Company had a net loss of $6,111,883 and $9,974,398, respectively. Continued losses may adversely affect the liquidity of the Company in the future. Therefore, the factors noted above raise substantial doubt about our ability to continue as a going concern. The recoverability of a major portion of the recorded asset amounts shown in the accompanying balance sheets is dependent upon continued operations of the Company, which in turn is dependent upon the Company's ability to raise additional capital, obtain financing and to succeed in its future operations. The financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern. The Company’s existence is dependent upon management’s ability to develop profitable operations and resolve its liquidity problems.	The Company's financial statements are prepared using the generally accepted accounting principles applicable to a going concern, which contemplates the realization of assets and liquidation of liabilities in the normal course of business. At June 30, 2022 and 2021, the Company had $1,065,945 and $962,540 in cash and $3,002,259 in negative working capital and $677,257 in working capital, respectively. For the year ended June 30, 2022 and 2021, the Company had a net loss of $15,882,195 and $2,702,602, respectively. Continued losses may adversely affect the liquidity of the Company in the future. Therefore, the factors noted above raise substantial doubt about our ability to continue as a going concern. The recoverability of a major portion of the recorded asset amounts shown in the accompanying balance sheets is dependent upon continued operations of the Company, which in turn is dependent upon the Company's ability to raise additional capital, obtain financing and to succeed in its future operations. The financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern. The Company’s existence is dependent upon management’s ability to develop profitable operations and resolve its liquidity problems.
Principles of Consolidation	The consolidated financial statements include the accounts of Xeriant, Inc., American Aviation Technologies, LLC, and Eco-Aero, LLC. All significant intercompany balances and transactions have been eliminated.	The consolidated financial statements include the accounts of Xeriant, Inc., American Aviation Technologies, LLC, and Eco-Aero, LLC. All significant intercompany balances and transactions have been eliminated.
Use of Estimates	The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. The most significant assumptions and estimates relate to the valuation of beneficial conversion features and warrants associated with convertible debt. Actual results could differ from these estimates.	The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. The most significant assumptions and estimates relate to the valuation of beneficial conversion features and warrants associated with convertible debt. Actual results could differ from these estimates.
Fair Value Measurements and Fair Value of Financial Instruments	The Company adopted ASC Topic 820, Fair Value Measurements. ASC Topic 820 clarifies the definition of fair value, prescribes methods for measuring fair value, and establishes a fair value hierarchy to classify the inputs used in measuring fair value as follows: Level 1: Inputs are unadjusted quoted prices in active markets for identical assets or liabilities available at the measurement date. Level 2: Inputs are unadjusted quoted prices for similar assets and liabilities in active markets, quoted prices for identical or similar assets and liabilities in markets that are not active, inputs other than quoted prices that are observable, and inputs derived from or corroborated by observable market data. Level 3: Inputs are unobservable inputs which reflect the reporting entity’s own assumptions on what assumptions the market participants would use in pricing the asset or liability based on the best available information. The estimated fair value of certain financial instruments, including all current liabilities are carried at historical cost basis, which approximates their fair values because of the short-term nature of these instruments. The inputs to the valuation methodology of stock options and warrants were under level 3 fair value measurements.	The Company adopted ASC Topic 820, Fair Value Measurements. ASC Topic 820 clarifies the definition of fair value, prescribes methods for measuring fair value, and establishes a fair value hierarchy to classify the inputs used in measuring fair value as follows: Level 1: Inputs are unadjusted quoted prices in active markets for identical assets or liabilities available at the measurement date. Level 2: Inputs are unadjusted quoted prices for similar assets and liabilities in active markets, quoted prices for identical or similar assets and liabilities in markets that are not active, inputs other than quoted prices that are observable, and inputs derived from or corroborated by observable market data. Level 3: Inputs are unobservable inputs which reflect the reporting entity's own assumptions on what assumptions the market participants would use in pricing the asset or liability based on the best available information. The estimated fair value of certain financial instruments, including all current liabilities are carried at historical cost basis, which approximates their fair values because of the short-term nature of these instruments. The inputs to the valuation methodology of stock options and warrants were under level 3 fair value measurements.
Cash and Cash Equivalents	For purposes of the Statements of Cash Flows, the Company considers highly liquid investments with an original maturity of three months or less to be cash equivalents. The Company has no cash equivalents.	For purposes of the Statements of Cash Flows, the Company considers highly liquid investments with an original maturity of three months or less to be cash equivalents. The Company has no cash equivalents.
Convertible Debentures	If the conversion features of conventional convertible debt provide for a rate of conversion that is below market value at issuance, this feature is characterized as a beneficial conversion feature (“BCF”). A BCF is recorded by the Company as a debt discount pursuant to ASC Topic 470-20 “Debt with Conversion and Other Options.” In those circumstances, the convertible debt is recorded net of the discount related to the BCF, and the Company amortizes the discount to interest expense, over the life of the debt. During the year ended June 30, 2022, the Company recorded a BCF in the amount of $2,615,419.	If the conversion features of conventional convertible debt provide for a rate of conversion that is below market value at issuance, this feature is characterized as a beneficial conversion feature ("BCF"). A BCF is recorded by the Company as a debt discount pursuant to ASC Topic 470-20 "Debt with Conversion and Other Options." In those circumstances, the convertible debt is recorded net of the discount related to the BCF, and the Company amortizes the discount to interest expense, over the life of the debt. During the year ended June 30, 2022, the Company recorded a BCF in the amount of $2,615,419.
Stock-based Compensation	The Company measures the cost of employee services received in exchange for equity incentive awards based on the grant date fair value of the award. The Company uses the Black-Scholes valuation model to calculate the fair value of stock options granted to employees or consultants. Stock-based compensation expense is recognized over the period during which the employee is required to provide services in exchange for the award, which is usually the vesting period.
Research and Development Expenses	Expenditures for research and development are expensed as incurred. The Company incurred research and development expenses of $0 and $5,200,219 for the six months ended December 31, 2022 and 2021, respectively. Advertising and Marketing Expenses The Company expenses advertising and marketing costs as they are incurred. The Company recorded advertising expenses in the amount of $21,421 and $164,713 for the six months ended December 31, 2022 and 2021, respectively. Income Taxes The Company recognizes the effect of income tax positions only if those positions are more likely than not of being sustained. Recognized income tax positions are measured at the largest amount that is more likely than not of being realized. Changes in recognition or measurement are reflected in the period in which the change in judgment occurs. The Company records interest and penalties related to unrecognized tax benefits as a component of general and administrative expenses. Our consolidated federal tax return and any state tax returns are not currently under examination. The Company follows Accounting Standards Codification subtopic 740-10, Income Taxes (“ASC 740-10”) for recording the provision for income taxes. Deferred tax assets and liabilities are computed based upon the difference between the financial statement and income tax basis of assets and liabilities using the enacted marginal tax rate applicable when the related asset or liability is expected to be realized or settled. Deferred income tax expenses or benefits are based on the changes in the asset or liability during each period. If available evidence suggests that it is more likely than not that some portion or all of the deferred tax assets will not be realized, a valuation allowance is required to reduce the deferred tax assets to the amount that is more likely than not to be realized. Future changes in such valuation allowance are included in the provision for deferred income taxes in the period of change. Deferred income taxes may arise from temporary differences resulting from income and expense items reported for financial accounting and tax purposes in different periods. Basic Income (Loss) Per Share Under the provisions of ASC 260, “Earnings per Share,” basic loss per common share is computed by dividing net loss available to common shareholders by the weighted average number of shares of common stock outstanding for the periods presented. Diluted net loss per share reflects the potential dilution that could occur if securities or other contracts to issue common stock were exercised or converted into common stock or resulted in the issuance of common stock that would then share in the income of the Company, subject to anti-dilution limitations.	Expenditures for research and development are expensed as incurred. The Company incurred research and development expenses of $5,267,581 and $373,112 for the years ended June 30, 2022 and 2021, respectively.
Advertising and Marketing Expenses	The Company expenses advertising and marketing costs as they are incurred. The Company recorded advertising expenses in the amount of $21,421 and $164,713 for the six months ended December 31, 2022 and 2021, respectively. Income Taxes The Company recognizes the effect of income tax positions only if those positions are more likely than not of being sustained. Recognized income tax positions are measured at the largest amount that is more likely than not of being realized. Changes in recognition or measurement are reflected in the period in which the change in judgment occurs. The Company records interest and penalties related to unrecognized tax benefits as a component of general and administrative expenses. Our consolidated federal tax return and any state tax returns are not currently under examination. The Company follows Accounting Standards Codification subtopic 740-10, Income Taxes (“ASC 740-10”) for recording the provision for income taxes. Deferred tax assets and liabilities are computed based upon the difference between the financial statement and income tax basis of assets and liabilities using the enacted marginal tax rate applicable when the related asset or liability is expected to be realized or settled. Deferred income tax expenses or benefits are based on the changes in the asset or liability during each period. If available evidence suggests that it is more likely than not that some portion or all of the deferred tax assets will not be realized, a valuation allowance is required to reduce the deferred tax assets to the amount that is more likely than not to be realized. Future changes in such valuation allowance are included in the provision for deferred income taxes in the period of change. Deferred income taxes may arise from temporary differences resulting from income and expense items reported for financial accounting and tax purposes in different periods. Basic Income (Loss) Per Share Under the provisions of ASC 260, “Earnings per Share,” basic loss per common share is computed by dividing net loss available to common shareholders by the weighted average number of shares of common stock outstanding for the periods presented. Diluted net loss per share reflects the potential dilution that could occur if securities or other contracts to issue common stock were exercised or converted into common stock or resulted in the issuance of common stock that would then share in the income of the Company, subject to anti-dilution limitations.	The Company expenses advertising and marketing costs as they are incurred. The Company recorded advertising expenses in the amount of $651,567 and $1,047,120 for the years ended June 30, 2022 and 2021, respectively.
Income Taxes	The Company recognizes the effect of income tax positions only if those positions are more likely than not of being sustained. Recognized income tax positions are measured at the largest amount that is more likely than not of being realized. Changes in recognition or measurement are reflected in the period in which the change in judgment occurs. The Company records interest and penalties related to unrecognized tax benefits as a component of general and administrative expenses. Our consolidated federal tax return and any state tax returns are not currently under examination. The Company follows Accounting Standards Codification subtopic 740-10, Income Taxes (“ASC 740-10”) for recording the provision for income taxes. Deferred tax assets and liabilities are computed based upon the difference between the financial statement and income tax basis of assets and liabilities using the enacted marginal tax rate applicable when the related asset or liability is expected to be realized or settled. Deferred income tax expenses or benefits are based on the changes in the asset or liability during each period. If available evidence suggests that it is more likely than not that some portion or all of the deferred tax assets will not be realized, a valuation allowance is required to reduce the deferred tax assets to the amount that is more likely than not to be realized. Future changes in such valuation allowance are included in the provision for deferred income taxes in the period of change. Deferred income taxes may arise from temporary differences resulting from income and expense items reported for financial accounting and tax purposes in different periods.	The Company recognizes the effect of income tax positions only if those positions are more likely than not of being sustained. Recognized income tax positions are measured at the largest amount that is more likely than not of being realized. Changes in recognition or measurement are reflected in the period in which the change in judgment occurs. The Company records interest and penalties related to unrecognized tax benefits as a component of general and administrative expenses. Our consolidated federal tax return and any state tax returns are not currently under examination. The Company follows Accounting Standards Codification subtopic 740-10, Income Taxes ("ASC 740-10") for recording the provision for income taxes. Deferred tax assets and liabilities are computed based upon the difference between the financial statement and income tax basis of assets and liabilities using the enacted marginal tax rate applicable when the related asset or liability is expected to be realized or settled. Deferred income tax expenses or benefits are based on the changes in the asset or liability during each period. If available evidence suggests that it is more likely than not that some portion or all of the deferred tax assets will not be realized, a valuation allowance is required to reduce the deferred tax assets to the amount that is more likely than not to be realized. Future changes in such valuation allowance are included in the provision for deferred income taxes in the period of change. Deferred income taxes may arise from temporary differences resulting from income and expense items reported for financial accounting and tax purposes in different periods.
Basic Income (Loss) Per Share	Under the provisions of ASC 260, “Earnings per Share,” basic loss per common share is computed by dividing net loss available to common shareholders by the weighted average number of shares of common stock outstanding for the periods presented. Diluted net loss per share reflects the potential dilution that could occur if securities or other contracts to issue common stock were exercised or converted into common stock or resulted in the issuance of common stock that would then share in the income of the Company, subject to anti-dilution limitations. The table below presents the computation of basic and diluted earnings per share for the six months ended December 31, 2022 and 2021: For the six months ended December 31, 2022 For the six months ended December 30, 2021 Numerator: Net loss $ (6,097,151 ) $ (6,759,529 ) Denominator: Weighted average common shares outstanding—basic 369,415,435 328,392,903 Dilutive common stock equivalents - - Weighted average common shares outstanding—diluted 369,415,435 328,392,903 Net loss per share: Basic $ (0.02 ) $ (0.02 ) Diluted $ (0.02 ) $ (0.02 )	Under the provisions of ASC 260, “Earnings per Share,” basic loss per common share is computed by dividing net loss available to common shareholders by the weighted average number of shares of common stock outstanding for the periods presented. Diluted net loss per share reflects the potential dilution that could occur if securities or other contracts to issue common stock were exercised or converted into common stock or resulted in the issuance of common stock that would then share in the income of the Company, subject to anti-dilution limitations. The table below presents the computation of basic and diluted earnings per share for the years ended June 30, 2022 and 2021: For the year ended June 30, 2022 For the year ended June 30, 2021 Numerator: Net loss $ (15,882,195 ) $ (2,702,602 ) Denominator: Weighted average common shares outstanding—basic 345,160,167 225,497,197 Dilutive common stock equivalents - - Weighted average common shares outstanding—diluted 345,160,167 225,497,197 Net loss per share: Basic $ (0.05 ) $ (0.01 ) Diluted $ (0.05 ) $ (0.01 )
Stock-based Compensation		The Company measures the cost of employee services received in exchange for equity incentive awards based on the grant date fair value of the award. The Company uses the Black-Scholes valuation model to calculate the fair value of stock options granted to employees or consultants. Stock-based compensation expense is recognized over the period during which the employee is required to provide services in exchange for the award, which is usually the vesting period.

SUMMARY OF SIGNIFICANT ACCOUN_3

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)	6 Months Ended	12 Months Ended
	Dec. 31, 2022	Jun. 30, 2022
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
Schedule of Earnings per share basic and diluted	For the six months ended December 31, 2022 For the six months ended December 30, 2021 Numerator: Net loss $ (6,097,151 ) $ (6,759,529 ) Denominator: Weighted average common shares outstanding—basic 369,415,435 328,392,903 Dilutive common stock equivalents - - Weighted average common shares outstanding—diluted 369,415,435 328,392,903 Net loss per share: Basic $ (0.02 ) $ (0.02 ) Diluted $ (0.02 ) $ (0.02 )	For the year ended June 30, 2022 For the year ended June 30, 2021 Numerator: Net loss $ (15,882,195 ) $ (2,702,602 ) Denominator: Weighted average common shares outstanding—basic 345,160,167 225,497,197 Dilutive common stock equivalents - - Weighted average common shares outstanding—diluted 345,160,167 225,497,197 Net loss per share: Basic $ (0.05 ) $ (0.01 ) Diluted $ (0.05 ) $ (0.01 )

OPERATING LEASE RIGHT OF USE _2

OPERATING LEASE RIGHT OF USE ASSET AND OPERATING LEASE LIABILITY (Tables)	6 Months Ended	12 Months Ended
	Dec. 31, 2022	Jun. 30, 2022
OPERATING LEASE RIGHT OF USE ASSET AND OPERATING LEASE LIABILITY
Summary of Operating lease liability	Operating lease liability is summarized below: December 31, 2022 Office lease $ 117,585 Less: current portion (50,647 ) Long term portion 66,938 Maturity of the lease liability is as follows: Fiscal year ending June 30, 2023 30,491 Fiscal year ending June 30, 2024 62,201 Fiscal year ending June 30, 2025 37,112 129,803 Present value discount (12,218 ) Lease liability $ 117,585
Summary of Right-of-use assets, net	Right-of-use asset is summarized below: December 31, 2022 Office lease $ 220,448 Less: accumulated amortization (114,209 ) Right -of- use asset, net $ 106,239	Right-of-use asset is summarized below: June 30, 2022 Office lease $ 220,448 Less: accumulated amortization (92,106 ) Right -of- use asset, net $ 128,342 Operating lease liability is summarized below: June 30, 2022 Office lease $ 141,160 Less: current portion (48,963 ) Long term portion 92,197 Maturity of the lease liability is as follows: Fiscal year ending June 30, 2023 60,392 Fiscal year ending June 30, 2024 62,201 Fiscal year ending June 30, 2025 37,112 159,705 Present value discount (18,545 ) Lease liability $ 141,160
Schedule of rent periods		November 1, 2019 to October 31, 2020 $ 4,367 November 1, 2020 to October 31, 2021 $ 4,498 November 1, 2021 to October 31, 2022 $ 4,633 November 1, 2022 to October 31, 2023 $ 4,772 November 1, 2023 to October 31, 2024 $ 4,915 November 1, 2024 to January 31, 2025 $ 5,063
Schedule of Rent periods	November 1, 2019 to October 31, 2020 $ 4,367 November 1, 2020 to October 31, 2021 $ 4,498 November 1, 2021 to October 31, 2022 $ 4,633 November 1, 2022 to October 31, 2023 $ 4,772 November 1, 2023 to October 31, 2024 $ 4,915 November 1, 2024 to January 31, 2025 $ 5,063

CONVERTIBLE NOTES PAYABLE (Tabl

CONVERTIBLE NOTES PAYABLE (Tables)	6 Months Ended	12 Months Ended
	Dec. 31, 2022	Jun. 30, 2022
CONVERTIBLE NOTES PAYABLE
Schedule of convertible notes payable	December 31, June 30, Convertible Notes Payable 2022 2022 Convertible notes payable issued October 27, 2021 (0% interest) – Auctus Fund LLC $ 5,850,000 $ 6,050,000 Total face value 5,850,000 6,050,000 Less unamortized discount - (2,113,815 ) Carrying value $ 5,850,000 $ 3,936,185	June 30, June 30, Convertible Notes Payable 2022 2021 Convertible notes payable issued January 5, 2021 (6% interest) $ - $ 25,000 Convertible notes payable issued January 11, 2021 (6% interest) - 142,550 Convertible notes payable issued August 9, 2021 (6% interest) - - Convertible notes payable issued August 10, 2021 (6% interest) - - Convertible notes payable issued October 27, 2021 (0% interest) – Auctus Fund LLC 6,050,000 - Total face value 6,050,000 167,550 Less unamortized discount (2,113,815 ) (9,354 ) Carrying value $ 3,936,185 $ 158,196
Schedule of loss on extinguishment on convertible debt instrument	Reacquisition Price: Modified convertible debt instrument 5,950,000 Fair value of warrants 1,918,393 Cash payment 100,000 Carrying Value of Original Instrument Original convertible debt instrument 6,050,000 Debt discount - warrant (707,585 ) Original issue discount (341,692 ) Debt discount - BCF (602,696 ) Carrying value of original debt 4,398,027 Loss on extinguishment 3,570,366 Reacquisition Price: Modified convertible debt instrument 5,850,000 Fair value of warrants 689,621 Accrued Short-term Liability 100,000 Carrying Value of Original Instrument Carrying value of original debt 5,950,000 Loss on extinguishment 689,621

NON-CONTROLLING INTEREST (Table

NON-CONTROLLING INTEREST (Tables)	12 Months Ended
	Jun. 30, 2022
NON-CONTROLLING INTEREST
Schedule of stock options activity	Number of Options Weighted- Average Exercise Price Weighted- Average Contractual Term (in years) Aggregate Intrinsic Value Outstanding at June 30, 2021 - $ - Granted 21,250,000 0.12 Exercised - - Canceled - - Outstanding at June 30, 2022 21,250,000 $ 0.12 2.1 $ - Exercisable at June 30, 2022 9,375,000 $ 0.12 2.1 $ -
Schedule of Black-Scholes process	Quoted market price on valuation date $0.169 - $0.23 Exercise prices $0.12 Range of expected term 1.55 Years – 2.49 Years Range of market volatility: Range of equivalent volatility 215.12% - 275.73% Range of interest rates 0.20% - 0.47%
Schedule of stock warrants activity	Number of Warrants Weighted- Average Exercise Price Weighted- Average Contractual Term (in years) Aggregate Intrinsic Value Outstanding at June 30, 2021 8,848,333 $ 0.03 0.94 - Granted 50,968,828 0.1187 4.6 - Exercised (4,305,000 ) - Canceled - - Outstanding at June 30, 2022 55,512,161 $ 0.111 4.0 $ - Vested and expected to vest at June 30, 2022 55,512,161 $ 0.111 4.0 $ - Exercisable at June 30, 2022 55,512,161 $ 0.111 4.0 $ -

EQUITY (Tables)

EQUITY (Tables)	6 Months Ended
	Dec. 31, 2022
EQUITY
Summary of Significant inputs and results arising from the black-scholes	Quoted market price on valuation date $ 0.169 - $0.23 Exercise prices $ 0.12 Range of expected term 1.55 Years – 2.49 Years Range of market volatility: Range of equivalent volatility 215.12% - 275.73 % Range of interest rates 0.20% - 0.47 %

INCOME TAXES (Tables)

INCOME TAXES (Tables)	12 Months Ended
	Jun. 30, 2020
INCOME TAXES
Schedule of components of deferred income tax assets	At June 30, 2022 and 2021, the significant components of the deferred tax assets are summarized below: 2022 2021 Deferred income tax asset Net operating loss carryforwards $ 5,860,409 3,237,960 Book to tax differences in intangible assets - Total deferred income tax asset 5,860,409 3,237,960 Less: valuation allowance (5,860,409 ) (3,237,960 ) Total deferred income tax asset $ — $ —

SUMMARY OF SIGNIFICANT ACCOUN_4

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) - USD ($)	6 Months Ended		12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Jun. 30, 2022	Jun. 30, 2021
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
Net loss	$ (6,097,151)	$ (6,759,529)
Numerator:
Weighted average common shares outstanding-basic	369,415,435	328,392,903	345,160,167	225,497,197
Weighted average common shares outstanding-diluted	369,415,435	328,392,903	345,160,167	225,497,197
Basic	$ (0.02)	$ (0.02)	$ (0.05)	$ (0.01)
Net Loss	$ (6,111,883)	$ 9,974,398	$ (15,882,195)	$ (2,702,602)
Diluted	$ (0.02)	$ (0.02)	$ (0.05)	$ (0.01)
Denominator:
Dilutive common stock equivalents			0	0

SUMMARY OF SIGNIFICANT ACCOUN_5

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) - USD ($)	3 Months Ended				6 Months Ended		12 Months Ended
	Dec. 31, 2022	Sep. 30, 2022	Dec. 31, 2021	Sep. 30, 2021	Dec. 31, 2022	Dec. 31, 2021	Jun. 30, 2022	Jun. 30, 2021
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
Research and development expenses	$ 0		$ 2,859,644		$ 0	$ 5,200,219	$ 5,267,581	$ 373,112
Cash	119,593				119,593		1,065,945	962,540
Working capital	(5,947,134)				(5,947,134)		(3,002,259)	677,257
Net Loss	(1,294,362)	$ (4,817,521)	(5,526,486)	$ (4,447,915)	(6,111,883)	(9,974,398)	(15,882,195)	(2,702,602)
Advertising expenses					21,421	164,713	651,567	1,047,120
Net loss	$ 1,294,362	$ 4,817,521	$ 5,526,486	$ 4,447,915	$ 6,111,883	$ 9,974,398	15,882,195	2,702,602
Debt instrument, convertible, beneficial conversion feature							2,615,419
Offering costs							$ 0	$ 0
Income tax positions percentage description							greater than 50%

JOINT VENTURE (Details)

JOINT VENTURE (Details) - USD ($)	Dec. 31, 2022	Jun. 30, 2022	Jun. 30, 2021
Cash	$ 119,593	$ 1,065,945	$ 962,540
Total Assets	363,084	1,269,676	$ 1,145,529
Joint Venture With XTI Aircraft [Member]
Cash	4,392	4,516
Due to Xeriant Inc.	5,479,547	5,479,547
Total Assets	$ 5,483,939	$ 5,484,063

JOINT VENTURE (Details Narrativ

JOINT VENTURE (Details Narrative) - USD ($)		1 Months Ended
	Apr. 02, 2022	Aug. 01, 2022	May 31, 2021	Dec. 31, 2022	Jun. 30, 2022	May 07, 2021	Mar. 31, 2021	Mar. 22, 2021	Nov. 24, 2020	Nov. 17, 2020	Aug. 26, 2020
Purchase number of share common stock		25,000,000
Exercise price				$ 0.09	$ 0.12	$ 0.12	$ 0.12	$ 0.28	$ 0.015	$ 0.015	$ 0.049
Joint Venture With XTI Aircraft [Member]
Initial Deposit			$ 1,000,000
Ownership owned percentage			50%
financial commitment agreegate amount			$ 10,000,000
Investment obligation			$ 10,000,000
Joint Venture With Movychem [Member]
Ownership owned percentage	50%
Pending payments	$ 25,000
Contribution amount				$ 280,656	$ 115,356
Description about intellectual property	Movychem is transferring to the Joint Venture all of its interest to the know-how and intellectual property relating to Retacell® exclusive of all of all patents, and the Company is contributing the amount of $2,600,000 payable (a) $600,000 at the rate of $25,000 per month over a 24 month period and (b) $2,000,000 within five business days of a closing of a financing in which the Company receives net proceeds of at least $3,000,000 but in no event later than six months from the Effective Date
Company payment	$ 2,000,000
Purchase number of share common stock	170,000,000
Exercise price	$ 0.01

CONCENTRATION OF CREDIT RISKS (

CONCENTRATION OF CREDIT RISKS (Details Narrative) - USD ($)	6 Months Ended	12 Months Ended
	Dec. 31, 2022	Jun. 30, 2022
CONCENTRATION OF CREDIT RISKS
Cash in excess of FDIC insurance	$ 0	$ 811,429

OPERATING LEASE RIGHT OF USE _3

OPERATING LEASE RIGHT OF USE ASSET AND OPERATING LEASE LIABILITY (Details) - USD ($)	6 Months Ended	12 Months Ended
	Dec. 31, 2022	Jun. 30, 2022
November 1, 2022 to October 31, 2023 [Member]
Base rent	$ 4,772	$ 4,772
November 1 2020 to October 1 2021 [Member]
Base rent	4,498	4,498
November 1 2023 to October 1 2024 [Member]
Base rent	4,915	4,915
November 1, 2024 to January 31, 2025 [Member]
Base rent	5,063	5,063
November 1, 2021 to October 31, 2022 [Member]
Base rent	4,633	4,633
November 1, 2019 to October 31, 2020 [Member]
Base rent	$ 4,367	$ 4,367

OPERATING LEASE RIGHT OF USE _4

OPERATING LEASE RIGHT OF USE ASSET AND OPERATING LEASE LIABILITY (Details 1) - USD ($)	Dec. 31, 2022	Jun. 30, 2022
OPERATING LEASE RIGHT OF USE ASSET AND OPERATING LEASE LIABILITY
Office lease	$ 220,448	$ 220,448
Less accumulated amortization	(114,209)	(92,106)
Right-of-use assets net	$ 106,239	$ 128,342

OPERATING LEASE RIGHT OF USE _5

OPERATING LEASE RIGHT OF USE ASSET AND OPERATING LEASE LIABILITY (Details 2) - USD ($)	Dec. 31, 2022	Jun. 30, 2022	Jun. 30, 2021
OPERATING LEASE RIGHT OF USE ASSET AND OPERATING LEASE LIABILITY
Office lease	$ 117,585	$ 141,160
Less current portion	(50,647)	(48,963)
Long term portion	66,938	92,197	$ 141,160
Maturity of the lease liability is as follows
Fiscal year ending June 30 2023	30,491	60,392
Fiscal year ending June 30 2024	62,201	62,201
Fiscal year ending June 30 2025	37,112	37,112
Lease liability Gross	129,803	159,705
Present value discount	(12,218)	(18,545)
Lease liability	$ 117,585	$ 141,160

OPERATING LEASE RIGHT OF USE _6

OPERATING LEASE RIGHT OF USE ASSET AND OPERATING LEASE LIABILITY (Details Narrative) - USD ($)	6 Months Ended	12 Months Ended
	Dec. 31, 2022	Jun. 30, 2022
Borrowing Interest Rate	10%	10%
Prepaid rent	$ 4,659	$ 4,659
Lease Agreement [Member]
Capital Leases Description		The Company leases 2,911 square feet of office space located in the Research Park at Florida Atlantic University, Innovation Centre 1, 3998 FAU Boulevard, Suite 309, Boca Raton, Florida

EXCHANGE AGREEMENT (Details Nar

EXCHANGE AGREEMENT (Details Narrative) - USD ($)	1 Months Ended
	Apr. 16, 2019	Dec. 31, 2022	Jun. 30, 2022	Jun. 30, 2021	Sep. 30, 2019
Banjo & Matilda, Inc and American Aviation Technologies LLC [Member] | Exchange Agreement [Member]
Business Acquisition, Percentage of Voting Interests Acquired	100%
Business Combination, consideration transferred, Equity Interest of acquirer, series A preferred stock, Percentage	86.39%
Series A Preferred Shares [Member]
Preferred stock, shares issued		769,895	781,132	788,270
Series A Preferred Shares [Member] | Xeriant [Member]
Preferred stock, shares issued as compensation					170,000
Preferred stock, shares issued					193,637
Liabilities					$ 2,608,224

CONVERTIBLE NOTES PAYABLE (Deta

CONVERTIBLE NOTES PAYABLE (Details) - USD ($)	Dec. 31, 2022	Jun. 30, 2022	Jun. 30, 2021
Total face value	$ 5,850,000	$ 6,050,000	$ 167,550
Less unamortized discount	0	(2,113,815)	(9,354)
Carrying value	5,850,000	3,936,185	158,196
Convertible notes payable issued January 5, 2021
Total face value		0	25,000
Convertible notes payable issued January 11, 2021
Total face value		0	142,550
Convertible notes payable issued August 9, 2021
Total face value		0	0
Convertible notes payable issued August 10, 2021
Total face value		0	0
Convertible notes payable issued October 27, 2021
Total face value	$ 5,850,000	$ 6,050,000	$ 0

CONVERTIBLE NOTES PAYABLE (De_2

CONVERTIBLE NOTES PAYABLE (Details 1)	6 Months Ended
	Dec. 31, 2022 USD ($)
Reacquisition Price
Modified convertible debt instrument	$ 5,950,000
Fair value of warrants	1,918,393
Cash payment	100,000
Carrying Value of Original Instrument
Original convertible debt instrument	6,050,000
Debt discount - warrant	(707,585)
Original issue discount	(341,692)
Debt discount - BCF	(602,696)
Carrying value of original debt	4,398,027
Loss on an extinguishment	$ 3,570,366

CONVERTIBLE NOTES PAYABLE (De_3

CONVERTIBLE NOTES PAYABLE (Details 2)	6 Months Ended
	Dec. 31, 2022 USD ($)
Reacquisition Price
Modified convertible debt instrument	$ 5,850,000
Fair value of warrants	689,621
Accrued Short-term Liability	100,000
Carrying Value of Original Instrument
Carrying value of original debt	5,950,000
Loss on an extinguishment	$ 689,621

CONVERTIBLE NOTES PAYABLE (De_4

CONVERTIBLE NOTES PAYABLE (Details Narrative) - USD ($)		1 Months Ended					3 Months Ended		6 Months Ended		9 Months Ended	12 Months Ended
	Jan. 15, 2023	Feb. 15, 2023	Dec. 27, 2022	Jul. 26, 2022	Oct. 27, 2021	Aug. 26, 2020	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2022	Dec. 31, 2021	Mar. 31, 2021	Jun. 30, 2022	Jun. 30, 2021
Carrying value of convertible notes payable, net of discount							$ 5,850,000		$ 5,850,000			$ 3,936,185
Carrying value of Auctus note							5,850,000		5,850,000			3,936,185
Amortization of debt discount									461,482
Total face value							5,850,000		5,850,000			6,050,000	$ 167,550
Debt instrument converted principal amount					$ 6,050,000				0	$ 2,777,081		2,894,974	117,893
Carrying value of convertible notes payable, net of discount							5,850,000		5,850,000			3,936,185	158,196
Purchase price					5,142,500
Amortization of debt discount					$ 907,500		0	$ (1,264,931)	(461,842)	(1,413,959)		4,629,089	303,942
Conversion price					$ 0.1187
Aggregate warrant issued of common stock					50,968,828
Fair value of warrant					$ 2,777,081
Fair value of beneficial conversion feature associated with convertible debt Additional paid in capital												2,365,419
Offering price per share					75%
Professional fees					$ 433,550		78,568	102,484	168,628	132,025		444,012	190,693
Interest expenses												138,943	7,409
Loss on an extinguishment						$ 186,954	(689,621)	$ (4)	(4,259,987)	(536)	$ (186,954)	535
Amortization of debt discount									461,842	1,413,959		4,629,089	$ 303,912
Convertible notes payable, aggregate face value							130,000		130,000			$ 250,000
Secured Debt [Memebr] | Senior Secured Note [Member] | Auctus Fund, LLC [Member]
Original issue discount					907,500
Debt instrument converted principal amount					25,000
Purchase price					$ 5,142,500
Conversion price					$ 0.1187
Aggregate warrant issued of common stock					50,968,828
Exercise price					$ 0.1187
Fair value of warrant					$ 2,777,081
Fair value of beneficial conversion feature associated with convertible debt Additional paid in capital							2,365,419		2,365,419
Offering price per share					75%
Professional fees					$ 433,550
Secured Debt [Memebr] | Promissory Note [Member] | Auctus Fund, LLC [Member] | October 27, 2021 [Member]
Debt instrument converted principal amount			$ 6,050,000	$ 6,050,000	$ 6,050,000
Exercise price				$ 0.09
Maturity date			Mar. 15, 2023	Nov. 01, 2022
New warrant to purchase shares of Common Stock			25,000,000	25,000,000
Prepayment of the Note	$ 50,000	$ 50,000		$ 100,000
Loss on an extinguishment			$ 689,621	$ 3,570,366
Warrants [Member]
Warrants Issued												8,848,333
Exercise price												$ 0.025
Fair value												$ 156,225
Between September 27 2019 and Aug 10 2021 [Member]
Amortization of debt discount										1,413,959
Interest expenses										$ 4,014
Convertible notes payable, aggregate face value							892,300		892,300
Convertible note payable issued by AAT							$ 342,950		$ 342,950			$ 342,950
Conversion price description									Of the $892,300, $342,950 is convertible at $.0033 per share, $87,000 is convertible at $0.025 per share, $180,550 is convertible at $.03 per share, $31,800 is convertible at $0.003 per share, and the remaining $250,000 is convertible at $.06 per share			Of the $892,300, $342,950 is convertible at $.0033 per share, $87,000 is convertible at $0.025 per share, $180,550 is convertible at $.03 per share, $31,800 is convertible at $0.003 per share, and the remaining $250,000 is convertible at $.06 per share
Interest rate							6%		6%			6%
Debt Instrument Convertible Beneficial Conversion Feature remaining												$ 892,300

RELATED PARTY TRANSACTIONS (Det

RELATED PARTY TRANSACTIONS (Details Narrative) - USD ($)		1 Months Ended		3 Months Ended			6 Months Ended		12 Months Ended
	Jul. 13, 2022	Jul. 31, 2022	Aug. 26, 2020	Sep. 30, 2022	Dec. 31, 2021	Sep. 30, 2021	Dec. 31, 2022	Dec. 31, 2021	Jun. 30, 2022	Jun. 30, 2021
Stock issued during period, shares, issued for services	457,143	457,143
Stock issued during period, value, issued for services	$ 48,000		$ 200,454	$ 48,000	$ 116,104	$ 541,100			$ 761,954	$ 1,275,703
Keystone Business Development Partners [Member]
Consulting fees							$ 15,000	$ 15,000	40,425	20,000
Accrued liability									0	0
Ancient Investments, LLC
Consulting fees							100,000	74,000	184,000	98,000
Accrued liability							15,000		15,000	0
Edward DeFeudis
Consulting fees							52,000	52,000	122,000	40,000
Accrued liability							10,000		0
AMP Web Services
Consulting fees							35,000	$ 37,000	86,000	49,500
Accrued liability							$ 7,000		$ 7,000	$ 0
Stock issued during period, shares, issued for services			4,090,909
Stock issued during period, value, issued for services			$ 13,500

COMMITMENTS AND CONTINGENCIES (

COMMITMENTS AND CONTINGENCIES (Details Narrative) - USD ($)		1 Months Ended										3 Months Ended	6 Months Ended		9 Months Ended	12 Months Ended
	Mar. 07, 2021	Mar. 28, 2022	Jan. 20, 2022	Aug. 20, 2021	Aug. 19, 2021	Aug. 09, 2021	Jul. 28, 2021	Jul. 06, 2021	Jan. 22, 2021	Jan. 18, 2021	Oct. 27, 2020	Nov. 10, 2021	Dec. 31, 2022	Dec. 31, 2021	Mar. 31, 2021	Jun. 30, 2022	Jun. 30, 2021
Common shares cash amount paid per meeting													$ 0	$ 2,078,500	$ 1,548,000	$ 2,078,500	$ 1,648,000
Financial Advisory Agreements [Member]
Stock issued during priod shares new issues																500,000
Issued share payable												500,000				5,000,000
Financing fees description													Pay a financing fee of 1.5% of gross proceeds received by the Company up to $100,000,000; a financing fee of 1.25% of gross proceeds received by the Company from $100,000,000-$200,000,000, and a financing fee of 1% of gross proceeds received by the Company over $200,000,000			Pay a financing fee of 1.5% of gross proceeds received by the Company up to $100,000,000; a financing fee of 1.25% of gross proceeds received by the Company from $100,000,000-$200,000,000, and a financing fee of 1% of gross proceeds received by the Company over $200,000,000
M A Description					Pay a cash fee for entering into a transaction including, without limitation, a merger, acquisition or sale of stock or assets equal to one- and one-half percent (1.5%), or in the event a transaction is consummated with a party that was in communication with the Company prior to the date of this contract, then the fee shall equal one half percent (0.5%).								M&A fee of 1.5% of the value of a business or asset sold up to $50,000,000; an M&A fee of 1.25% of value of a business or asset sold from $50,000,000-$100,000,000, an M&A fee of 1% of value of a business or asset sold from $100,000,000-$200,000,000, and an M&A fee of 0.5% of value of a business or asset sold over $200,000,000			M&A fee of 1.5% of the value of a business or asset sold up to $50,000,000; an M&A fee of 1.25% of value of a business or asset sold from $50,000,000-$100,000,000, an M&A fee of 1% of value of a business or asset sold from $100,000,000-$200,000,000, and an M&A fee of 0.5% of value of a business or asset sold over $200,000,000
Financial Advisory Agreements One [Member]
Stock issued during priod shares new issues					2,225,000											2,225,000
Issue of initial shares																1,500,000
Cash fee percent of amount capital raised					7%								7%			7%
Issue common shares payable				2,225,000	2,225,000											2,225,000
Advisory Board [Member]
Common shares cash amount paid per meeting	$ 2,500	$ 2,500	$ 5,000	$ 2,500		$ 2,500	$ 2,500	$ 2,500	$ 2,500	$ 2,500	$ 2,500
Stock issued during priod shares new issues		150,000	250,000	100,000		50,000	250,000		25,000	50,000	300,000	500,000	5,000,000			500,000
Issue of initial shares																1,500,000
Additional bonus paid common shares issued for services				$ 25,000			$ 25,000	$ 25,000
Issued share payable												500,000
Issue of second tranche shares																50,000
Warrant options to common shares	50,000						5,000,000	5,000,000	25,000	100,000	300,000		10,000,000
Issue of remaining shares																500,000
Common stock shares issuedsold price per share							$ 0.12	$ 0.12
Common share opened a strategic bonus		25,000				25,000	5,000,000	250,000
Advisory Board [Member] | July 1 2020 [Member]
Common shares cash amount paid per meeting																$ 2,500
Stock issued during priod shares new issues										50,000						10,000,000
Additional bonus paid common shares issued for services																$ 25,000
Warrant options to common shares			2,250,000	4,000,000						25,000						1,000,000
Common stock shares issuedsold price per share			$ 0.12	$ 0.12												$ 0.12
Average market price																25%
Option to purchase shares																$ 5,000,000
Advisory Board [Member] | July 1 2021 [Member]
Common shares cash amount paid per meeting													$ 2,500
Stock issued during priod shares new issues										50,000			100,000
Additional bonus paid common shares issued for services													$ 25,000
Warrant options to common shares			2,250,000	4,000,000									1,000,000
Common stock shares issuedsold price per share			$ 0.12	$ 0.12									$ 0.12
Average market price													25%
Option to purchase shares													$ 5,000,000

EQUITY (Details)

EQUITY (Details) - $ / shares	6 Months Ended	12 Months Ended
	Dec. 31, 2022	Jun. 30, 2022	May 07, 2021	Mar. 31, 2021	Mar. 22, 2021	Nov. 24, 2020	Nov. 17, 2020	Aug. 26, 2020
Quoted market price on valuation date	$ 0.09	$ 0.12	$ 0.12	$ 0.12	$ 0.28	$ 0.015	$ 0.015	$ 0.049
Stock Option [Member]
Exercise price	0.12	0.12
Minimum [Member] | Stock Option [Member]
Quoted market price on valuation date	$ 0.169	$ 0.169
Range of expected term	1 year 6 months 18 days	1 year 6 months 18 days
Range of interest rate	0.20%	0.20%
Range of equivalent volatility	215.12%	215.12%
Maximum [Member] | Stock Option [Member]
Quoted market price on valuation date	$ 0.23	$ 0.23
Range of expected term	2 years 5 months 26 days	2 years 5 months 26 days
Range of interest rate	0.47%	0.47%
Range of equivalent volatility	275.73%	275.73%

EQUITY (Details Narrative)

EQUITY (Details Narrative) - USD ($)						1 Months Ended												3 Months Ended				6 Months Ended		9 Months Ended	12 Months Ended
	Jul. 13, 2022	Jul. 11, 2022	May 07, 2021	Feb. 09, 2021	Sep. 08, 2020	Oct. 24, 2022	Jul. 31, 2022	Apr. 26, 2021	Mar. 31, 2021	Mar. 22, 2021	Mar. 22, 2021	Jan. 29, 2021	Nov. 24, 2020	Nov. 17, 2020	Oct. 30, 2020	Aug. 26, 2020	Jul. 30, 2020	Dec. 31, 2022	Sep. 30, 2022	Dec. 31, 2021	Sep. 30, 2021	Dec. 31, 2022	Dec. 31, 2021	Mar. 31, 2021	Jun. 30, 2022	Jun. 30, 2021	Mar. 27, 2021	Feb. 15, 2021
Common stock authorized																		5,000,000,000				5,000,000,000			5,000,000,000	5,000,000,000
Common stock shares par value																		$ 0.00001				$ 0.00001			$ 0.00001	$ 0.00001
Common stock shares issued																		376,933,144				376,933,144			365,239,001	292,815,960
Additional common shares issued as financing costs																									845,936
Common stock shares outstanding																		376,933,144				376,933,144			365,239,001	292,815,960
Aggregate gross proceeds on exercise of warrant																									$ 128,550
Share issued for exchange conversion, shares		1,000,000				10,237,000																			7,138,000
Conversion of Series A Preferred to Common Stock, shares		1,000				10,237																			7,138
Aggregate relative fair value																									$ 134,927
Conversion of Stock in Principle amount				$ 127,150				$ 30,000			$ 23,000														167,550
Stock issued during period shares issued for services	457,143						457,143
Stock issued during period value issued for services	$ 48,000															$ 200,454			$ 48,000	$ 116,104	$ 541,100				761,954	$ 1,275,703
Conversion of Stock in accured interest				$ 2,709				$ 444			$ 853														4,985
Loss on settlement in debt																$ 186,954		$ (689,621)		(4)		$ (4,259,987)	$ (536)	$ (186,954)	$ 535
Common stock issued for prior period conversions of principal and interest				19,595,442				1,014,798			4,557,943														10,598,544
Conversion of convertible notes payable																		$ 130,000				$ 130,000			$ 250,000
Accrued interest																									$ 3,749
Common stock share issued for conversion																									4,229,680
Price per share			$ 0.12						$ 0.12	$ 0.28	$ 0.28		$ 0.015	$ 0.015		$ 0.049		$ 0.09				$ 0.09		$ 0.12	$ 0.12
Number of shares Options outstanding																										0
Number of shares Stock options exercisable																									9,375,000
Stock options weighted average remaining term																									2 years 1 month 6 days
Compensation expense																									$ 3,248,181
Fair value of stock option																									$ 3,964,207
Stock options issued																									21,250,000
Exercise price																									$ 0.12
Total unrecognized compensation																									$ 702,166
Stock issued during period shares issued for services																4,090,909									4,685,615
Number of warrants exercised																									4,308,600
Payment for service performed																$ 13,500
Common shares issued during period value																				$ 410,000	$ 1,668,500				$ 2,078,500	$ 1,648,000
Share sold during period, value			$ 100,000						$ 1,497,000	$ 13,800			$ 25,500	$ 25,500											2,078,500
Common shares issued during period value																						$ 0	2,078,500	$ 1,548,000	$ 2,078,500	$ 1,648,000
Share sold during period, shares			833,333						12,075,001	50,000			1,700,000	1,700,000											39,366,666
Preferred stock share converted																										44,367
Common stock share converted																										44,366,919
Spider Investments, LLC
Share returned to treasury																											41,000
March 22 2021 [Member]
Price per share										$ 0.46	$ 0.46														$ 0.05
Share sold during period, value										$ 22,750	$ 22,750
Share sold during period										50,000	50,000
Subscription Agreement [Member]
Common shares issued during period shares																									250,000
Common shares issued during period value																									$ 43,753
Advisory board Member
Price per share												$ 0.51			$ 0.044
Common stock shares issued for services												50,000			300,000
Common stock shares issued for services value												$ 25,500			$ 13,200
Investment Relation [Member] | December 1 2020 [Member]
Stock issued during period shares issued for services																									2,000,000
Stock issued during period value issued for services																									$ 100,000
Price per share																									$ 0.05
Investment Relation One [Member] | December 1 2020 [Member]
Stock issued during period shares issued for services																									18,000,000
Stock issued during period value issued for services																									$ 900,000
Price per share																									$ 0.05
CEO
Preferred stock shares issued																										1,000,000
Common Stock To Be Issued [Member]
Stock issued during period shares issued for services					96,835,648																				250,000
Stock issued during period value issued for services																									$ 45,950
Common Stock To Be Issued [Member] | Tranche One [Member]
Price per share																									$ 0.03
Common shares issued during period shares																	16,011,818								200,000
Common shares issued during period value																									$ 6,000
American Aviation Technologies LLC [Member]
Preferred stock, shares rescinded									1,250,001															1,250,001				990,000
Stock Option [Member]
Number of shares Options outstanding																		21,250,000				21,250,000
Number of shares Stock options exercisable																		15,375,000				15,375,000
Stock options weighted average remaining term																						1 year 4 months 17 days
Compensation expense																						$ 515,917	$ 1,887,545
Fair value of stock option																									$ 3,964,207
Stock options issued																									21,250,000
Exercise price																									$ 0.12
Total unrecognized compensation																		$ 186,199				$ 186,199
Stock Option [Member] | Minimum [Member]
Price per share																		$ 0.169				$ 0.169			0.169
Stock Option [Member] | Maximum [Member]
Price per share																		$ 0.23				$ 0.23			$ 0.23
Warrants [Member]
Aggregate gross proceeds on exercise of warrant																									$ 128,550
Aggregate relative fair value																		$ 2,777,081				$ 2,777,081
Number of warrants Outstanding																		105,512,161				105,512,161			55,512,161
Wighted average remaining useful life of warrants																						4 years
Number of warrants exercised																									4,305,000
Warrants [Member] | Minimum [Member]
Warrant term																						2 years			2 years
Warrant exercise price																						$ 0.1187			$ 0.1187
Warrants [Member] | Maximum [Member]
Warrant term																						5 years			5 years
Warrant exercise price																						$ 0.025			$ 0.025
Series B Preferred Shares [Member]
Preferred stock shares authorized																		100,000,000				100,000,000			100,000,000	100,000,000
Preferred stock shares par value																		$ 0.00001				$ 0.00001			$ 0.00001	$ 0.00001
Preferred stock shares designated																		1,000,000				1,000,000			1,000,000	1,000,000
Preferred stock shares issued																		1,000,000				1,000,000			1,000,000	1,000,000
Preferred stock shares outstanding																		1,000,000				1,000,000			1,000,000	1,000,000
Series A Preferred Shares [Member]
Preferred stock shares authorized																		100,000,000				100,000,000			100,000,000	100,000,000
Preferred stock shares designated																		3,500,000				3,500,000			3,500,000	3,500,000
Voting description																									100 votes to every one share of common stock
Conversion description																									1:1,000 basis
Preferred stock shares issued																		769,895				769,895			781,132	788,270
Preferred stock shares outstanding																		769,895				769,895			781,132	788,270
Preferred stock, shares rescinded									1,250,001															1,250,001	1,760,000
Series A Preferred Stock [Member]
Preferred stock shares authorized																									100,000,000	100,000,000
Preferred stock shares par value																									$ 0.00001	$ 0.00001
Preferred stock shares designated																									3,500,000	3,500,000
Preferred stock shares issued																									780,132	788,270
Preferred stock shares outstanding																									781,132	788,270
Preferred stock, shares rescinded																									990,000
Series A Preferred Stock shares [Member]
Share issued for exchange conversion, shares		1,000,000				10,237,000
Conversion of Series A Preferred to Common Stock, shares		1,000				10,237
Preferred stock shares authorized																		100,000,000				100,000,000			100,000,000
Preferred stock shares par value																		$ 0.00001				$ 0.00001			$ 0.00001
Preferred stock shares designated																		3,500,000				3,500,000			3,500,000
Voting description																						100 votes to every one share of common stock
Conversion description																						1:1,000 basis
Preferred stock shares issued																		769,895				769,895			781,132
Preferred stock shares outstanding																		769,895				769,895			781,132

NON-CONTROLLING INTEREST (Detai

NON-CONTROLLING INTEREST (Details)	12 Months Ended
	Jun. 30, 2022 USD ($) $ / shares shares
Number of Shares
Outstanding, Beginning	0
Grants	21,250,000
Exercised	0
Canceled	0
Outstanding at Ending | $	$ 21,250,000
Exercisable at Ending	9,375,000
Weighted Average Exercise Price
Outstanding, Beginning | $ / shares	$ 0
Grants | $ / shares	0.12
Exercised | $ / shares	$ 0
Canceled	0
Outstanding at Ending | $ / shares	$ 0.12
Exercisable at Ending | $ / shares	$ 0.12
Weighted Average Remaining Contractual Term
Outstanding at Ending	2 years 1 month 6 days
Exercisable at Ending	2 years 1 month 6 days
Aggregate Intrinsic Value
Outstanding at Ending | $	$ 0
Exercisable at Ending | $	$ 0

NON-CONTROLLING INTEREST (Det_2

NON-CONTROLLING INTEREST (Details 1) - $ / shares	6 Months Ended	12 Months Ended
	Dec. 31, 2022	Jun. 30, 2022	May 07, 2021	Mar. 31, 2021	Mar. 22, 2021	Nov. 24, 2020	Nov. 17, 2020	Aug. 26, 2020
Price per share	$ 0.09	$ 0.12	$ 0.12	$ 0.12	$ 0.28	$ 0.015	$ 0.015	$ 0.049
Stock Option [Member]
Exercise price	0.12	0.12
Minimum [Member] | Stock Option [Member]
Price per share	$ 0.169	$ 0.169
Range of expected term	1 year 6 months 18 days	1 year 6 months 18 days
Range of interest rate	0.20%	0.20%
Range of equivalent volatility	215.12%	215.12%
Maximum [Member] | Stock Option [Member]
Price per share	$ 0.23	$ 0.23
Range of expected term	2 years 5 months 26 days	2 years 5 months 26 days
Range of interest rate	0.47%	0.47%
Range of equivalent volatility	275.73%	275.73%

NON-CONTROLLING INTEREST (Det_3

NON-CONTROLLING INTEREST (Details 2)	12 Months Ended
	Jun. 30, 2022 $ / shares shares
Canceled	0
Weighted average contractual term [Member]
Weighted average contractual term, beginning	11 months 8 days
Weighted average contractual term, granted	4 years 7 months 6 days
Weighted average contractual term, Exercised	0 years
Weighted average contractual term, Canceled	0 years
Weighted average contractual term, ending	4 years
Weighted average contractual term, Vested and expected to vest	4 years
Weighted average contractual term, Exercisable	4 years
Weighted Average Exercise Price [Member]
Weighted average exercise price, beginning | $ / shares	$ 0.03
Weighted average exercise price, granted | $ / shares	0.1187
Weighted average exercise price, Exercised | $ / shares	0
Weighted average exercise price, Canceled | $ / shares	0
Weighted average exercise price, Ending | $ / shares	0.111
Weighted average exercise price, Vested and expected to vest | $ / shares	0.111
Weighted average exercise price, Exercisable | $ / shares	$ 0.111
Warrants [Member]
Outstanding, Beginning	8,848,333
Granted	50,968,828
Warrant Exercised	(4,305,000)
Canceled	0
Outstanding,Ending	55,512,161
Outstanding Vested and expected to vest	55,512,161
Outstanding Exercisable	55,512,161

NON-CONTROLLING INTEREST (Det_4

NON-CONTROLLING INTEREST (Details Narrative) - USD ($)	6 Months Ended	12 Months Ended
	Dec. 31, 2022	Jun. 30, 2022	Jun. 30, 2021	May 12, 2021	May 07, 2021	Mar. 31, 2021	Mar. 22, 2021	Nov. 24, 2020	Nov. 17, 2020	Aug. 26, 2020
Compensation expense		$ 3,248,181
Fair value of stock option		3,964,207
Aggregate gross proceeds on exercise of warrant		$ 128,550
Stock options issued		21,250,000
Stock options exercisable		9,375,000
Stock options weighted average remaining term		2 years 1 month 6 days
Price per share	$ 0.09	$ 0.12			$ 0.12	$ 0.12	$ 0.28	$ 0.015	$ 0.015	$ 0.049
Total unrecognized compensation		$ 702,166
Aggregate relative fair value		$ 134,927
Number of warrants exercised		4,308,600
American Aviation Technologies LLC [Member]
Return of total membership units				3,600,000
Ownership reduced percentage				64%
Warrants [Member]
Aggregate gross proceeds on exercise of warrant		$ 128,550
Number of warrants Outstanding	105,512,161	55,512,161
Aggregate relative fair value	$ 2,777,081
Number of warrants exercised		4,305,000
Wighted average remaining useful life of warrants	4 years
Warrants One [Member]
Aggregate gross proceeds on exercise of warrant		$ 128,550
Number of warrants Outstanding		55,512,161	8,848,333
Aggregate relative fair value		$ 2,777,081
Number of warrants exercised		4,305,000
Wighted average remaining useful life of warrants		4 years
Minimum [Member] | Warrants [Member]
Warrant term	2 years	2 years
Warrant exercise price	$ 0.1187	$ 0.1187
Maximum [Member] | Warrants [Member]
Warrant term	5 years	5 years
Warrant exercise price	$ 0.025	$ 0.025

INCOME TAXES (Details)

INCOME TAXES (Details) - USD ($)	Jun. 30, 2022	Jun. 30, 2021
Deferred income tax asset
Net operation loss carryforwards	$ 5,860,409	$ 3,237,960
Book to tax differences in intangible assets		0
Total deferred income tax asset	5,860,409	3,237,960
Less: valuation allowance	(5,860,409)	(3,237,960)
Total deferred income tax asset	$ 0	$ 0

SUBSEQUENT EVENTS (Details Narr

SUBSEQUENT EVENTS (Details Narrative) - USD ($)		1 Months Ended		6 Months Ended
	Jul. 13, 2022	Aug. 01, 2022	Jul. 31, 2022	Dec. 31, 2022	Jun. 30, 2022	Jun. 30, 2021	May 07, 2021	Mar. 31, 2021	Mar. 22, 2021	Nov. 24, 2020	Nov. 17, 2020	Aug. 26, 2020
Convertible notes				$ 130,000	$ 250,000
Converted common shares			1,000	1,300,000
Convertible notes discount				25%
Price per share				$ 0.09	$ 0.12		$ 0.12	$ 0.12	$ 0.28	$ 0.015	$ 0.015	$ 0.049
Common stock issued			1,000,000
Warrants issued period				5 years
Exercise price		$ 0.09
Prepayment of note Payable		$ 100,000
Stock issued during period shares issued for services	457,143		457,143
Warrants granted to purchase common stock		25,000,000
Total face value				$ 5,850,000	$ 6,050,000	$ 167,550
Convertible notes payable issued October 27, 2021
Total face value		$ 6,050,000